Identification

Name
Ibuprofen
Accession Number
DB01050  (APRD00372)
Type
Small Molecule
Groups
Approved
Description

Ibuprofen, a propionic acid derivative, is a prototypical nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties.

Structure
Thumb
Synonyms
  • (±)-2-(p-isobutylphenyl)propionic acid
  • (±)-ibuprofen
  • (±)-p-isobutylhydratropic acid
  • (±)-α-methyl-4-(2-methylpropyl)benzeneacetic acid
  • (4-isobutylphenyl)-α-methylacetic acid
  • (RS)-ibuprofen
  • 2-(4-isobutylphenyl)propanoic acid
  • 4-isobutylhydratropic acid
  • Ibuprophen
  • α-(4-isobutylphenyl)propionic acid
  • α-(p-isobutylphenyl)propionic acid
Product Ingredients
IngredientUNIICASInChI Key
Ibuprofen aluminumD0YGZ1VO1B61054-06-6QAZIXAUMDFPQRW-UHFFFAOYSA-K
Ibuprofen lysineN01ORX9D6S57469-77-9IHHXIUAEPKVVII-ZSCHJXSPSA-N
Ibuprofen potassium48304089JJ79261-49-7XJELUCTZEAQYGF-UHFFFAOYSA-M
Ibuprofen sodiumRM1CE97Z4N527688-20-6VTGPMVCGAVZLQI-UHFFFAOYSA-M
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo Ibuprofen Tab 600mgTablet600 mgOralApotex Corporation1984-12-31Not applicableCanada
CaldolorInjection800 mg/8mLIntravenousCumberland Pharmaceuticals2009-06-11Not applicableUs
CaldolorSolution100 mgIntravenousAlveda Pharmaceuticals Inc2012-06-15Not applicableCanada
Ibuprofen-600 Tab 600mgTablet600 mgOralPro Doc Limitee1986-12-312014-07-24Canada
Motrin Tablets 600mgTablet600 mgOralMcneil Consumer Healthcare Division Of Johnson & Johnson Inc1980-12-312004-07-22Canada
NeoProfenSolution10 mg/mLIntravenousRecordati Rare Diseases Inc2006-04-13Not applicableUs
PedeaInjection, solution5 mg/mlIntravenousOrphan Europe S.A.R.L.2004-07-29Not applicableEu
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AlivioTablet600 mg/600mgOralAlivio Medical Products, Llc2015-07-012017-11-04Us
AlivioTablet400 mg/400mgOralAlivio Medical Products, Llc2015-07-012017-11-04Us
AlivioTablet800 mg/800mgOralAlivio Medical Products, Llc2015-07-012017-11-04Us
Alti-ibuprofen Tab 600mgTablet600 mgOralAltimed Pharma Inc.1984-12-311999-09-17Canada
Anodyne IleKitFortus Pharma, Llc2017-10-16Not applicableUs
Comfort Pac with IbuprofenKitPd Rx Pharmaceuticals, Inc.2012-09-06Not applicableUs
IbuTablet400 mg/1OralDr Reddy's Laboratories2008-11-20Not applicableUs
IbuTablet600 mg/1OralUnit Dose Services2008-11-20Not applicableUs
IbuTablet800 mg/1OralSt. Marys Medical Park Pharmacy2016-01-08Not applicableUs
IbuTablet400 mg/1OralNu Care Pharmaceuticals,inc.2008-11-20Not applicableUs
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
7 Select Childrens IbuprofenSuspension100 mg/5mLOral7 Eleven2014-08-05Not applicableUs
7 Select IbuprofenCapsule, liquid filled200 mg/1Oral7 Eleven2018-02-02Not applicableUs
7 Select IbuprofenTablet, film coated200 mg/1Oral7 Eleven2014-08-07Not applicableUs
7 Select IbuprofenTablet, coated200 mg/1Oral7 Eleven2014-05-13Not applicableUs
Actiprofen - Caplet 200mgTablet200 mgOralBayer Inc Consumer Care1996-12-311999-11-03Canada
AdvilCapsule, liquid filled200 mg/1OralWyeth Consumer Healthcare Llc1995-04-10Not applicableUs
AdvilTablet, coated200 mg/1OralWyeth Consumer Healthcare Llc1984-05-18Not applicableUs
AdvilTablet, coated256 mg/1OralWyeth Consumer Healthcare Llc2013-07-08Not applicableUs
AdvilTablet, coated200 mg/1OralWyeth Consumer Healthcare Llc1984-05-18Not applicableUs
AdvilCapsule, liquid filled200 mg/1OralWyeth Consumer Healthcare Llc2017-03-08Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
10 Person ANSIIbuprofen + Acetaminophen + Acetylsalicylic acid + Bacitracin zinc + Benzalkonium chloride + Benzocaine + Ethanol + Lidocaine + Neomycin sulfate + Polymyxin B Sulfate + WaterKitGenuine First Aid2010-04-24Not applicableUs
25 Person ANSIIbuprofen + Acetaminophen + Acetylsalicylic acid + Bacitracin zinc + Benzalkonium chloride + Benzocaine + Ethanol + Isopropyl Alcohol + Lidocaine + Neomycin sulfate + Polymyxin B Sulfate + WaterKitGenuine First Aid2010-04-25Not applicableUs
50 Person ANSIIbuprofen + Acetaminophen + Acetylsalicylic acid + Bacitracin zinc + Benzalkonium chloride + Benzocaine + Ethanol + Isopropyl Alcohol + Lidocaine + Neomycin sulfate + Polymyxin B Sulfate + WaterKitGenuine First Aid2010-06-02Not applicableUs
7 Select Ibuprofen PMIbuprofen (200 mg/1) + Diphenhydramine citrate (38 mg/1)Tablet, film coatedOral7 Eleven2014-08-05Not applicableUs
7-Select Advil PMIbuprofen (200 mg/1) + Diphenhydramine citrate (38 mg/1)Tablet, coatedOralLil' Drug Store Products, Inc.2011-06-012017-12-31Us
Adventure Medical Kits 1-2 Person First AidIbuprofen (200 mg/1) + Acetaminophen (500 mg/1) + Acetylsalicylic acid (325 mg/1) + Bacitracin zinc (400 [iU]/1g) + Benzalkonium chloride (0.40 mL/100mL) + Benzocaine (6 mL/100mL) + Diphenhydramine hydrochloride (25 mg/1) + Ethanol (60 mL/100mL) + Neomycin sulfate (5 mg/1g) + Polymyxin B Sulfate (5000 [iU]/1g)KitTopicalTender Corp Dba Adventure Medical Kits2010-08-26Not applicableUs
Adventure Medical Kits 1-2 Person National Ski Patrol First AidIbuprofen (200 mg/1) + Acetaminophen (500 mg/1) + Acetylsalicylic acid (325 mg/1) + Bacitracin zinc (400 [iU]/1g) + Benzalkonium chloride (0.40 mL/100mL) + Benzocaine (6 mL/100mL) + Ethanol (60 mL/100mL) + Neomycin sulfate (5 mg/1g) + Polymyxin B Sulfate (5000 [iU]/1g)KitTender Corp Dba Adventure Medical Kits2010-08-26Not applicableUs
Adventure Medical Kits 1-4 Person First AidIbuprofen (200 mg/1) + Acetaminophen (500 mg/1) + Acetylsalicylic acid (325 mg/1) + Bacitracin zinc (400 [iU]/1g) + Benzalkonium chloride (0.40 mL/100mL) + Benzocaine (6 mL/100mL) + Diphenhydramine hydrochloride (25 mg/1) + Ethanol (60 mL/100mL) + Neomycin sulfate (5 mg/1g) + Polymyxin B Sulfate (5000 [iU]/1g)KitTopicalTender Corp Dba Adventure Medical Kits2010-08-26Not applicableUs
Advil Allergy and Congestion ReliefIbuprofen (200 mg/1) + Chlorpheniramine maleate (4 mg/1) + Phenylephrine hydrochloride (10 mg/1)TabletOralNavajo Manuracturing Company2016-09-16Not applicableUs
Advil Allergy and Congestion ReliefIbuprofen (200 mg/1) + Chlorpheniramine maleate (4 mg/1) + Phenylephrine hydrochloride (10 mg/1)Tablet, coatedOralPfizer2012-07-23Not applicableUs
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
IbuprofenIbuprofen (200 mg/1)TabletOralCardinal Health2011-06-022018-05-31Us
PrasteraIbuprofen + PrasteroneKitOralHealth Science Funding, Llc2014-04-04Not applicableUs
Theraprofen-60Ibuprofen + gamma-Aminobutyric acidKitPhysician Therapeutics Llc2011-07-192016-10-13Us
Theraprofen-800Ibuprofen + gamma-Aminobutyric acidKitPhysician Therapeutics Llc2011-02-072016-10-13Us
Theraprofen-90Ibuprofen + gamma-Aminobutyric acidKitPhysician Therapeutics Llc2011-02-072016-10-13Us
Topical PainIbuprofen (.1 g/100mL) + Diazepam (.1 g/100mL) + Hydrocodone (.1 g/100mL) + Tramadol (.1 g/100mL)CreamTopicalDr Marc's Manufacturing And Sales2016-02-232018-05-11Us
International/Other Brands
Act-3 (Healthcare Logistics) / Actiprofen (Sterling Health) / Adex (Dexxon) / Adran / Aktren (Bayer) / Alges-X (Axapharm) / Algoflex (Chinoin) / Algofren (Intermed) / Alivium (Bristol-Myers Squibb) / Artofen (Teva) / Betagesic (Adcock Ingram Pharmaceuticals) / Betaprofen (Be-Tabs Pharmaceuticals) / Bluton / Bonifen (Krka) / Brufen (Abbott) / Buburone (Towa Yakuhin) / Bugesic / Buprovil / Burana (Orion) / Butylenin / Calprofen (McNeil) / Cap-Profen (PERRIGO) / Children's Elixsure (Pfizer) / Children's Ibuprofen (Pfizer) / Dalsy (Abbott) / Dismenol (Merz) / Diverin / Dolgirid / Dolgit (Dolorgiet) / Dolofort / Doloraz / Dolormin / Dorival / Ebufac / EmuProfen / Epobron / Espidifen / Eve / Femadon / Fenbid / Fenpaed / Finalflex / Galprofen / Haltran / Herron Blue / i-profen / Ibalgin / Ibu-Attritin / IBU-Ratiopharm / Ibu-Vivimed / Ibuflam / Ibugel / Ibugesic / IbuHEXAL / Ibuleve / Ibum / Ibumax / Ibumetin / Ibumidol / Ibupain / Ibuprocin / Ibuprom / Ibuprosyn / Ibuprox / Ibustar / Ibutid / Ibux / Ibuxin / Inabrin / Inoven / Ipren / Junior Strength Motrin / Kratalgin / Lamidon / Lebrufen / Liptan / Lotem / Medicol / Medipren / Midol IB / Motrin / Mynosedin / Mypaid / Myprodol / Narfen / Naron Ace / Neobrufen / Nobfen / Nobgen / Norvectan / Nuprin / Nureflex / Nurofen / Orbifen / Panafen / Pediaprofen / Perifar / Profin / Ranfen / Rapidol / Ratiodolor / Rimafen / Roidenin / Rufen / Salvarina / Seclodin / Solpaflex / Speedpain NANO / Spidifen (Zambon) / Suspren / Tabalon / Tefin / Trendar / Unafen / Upfen / Urem
Categories
UNII
WK2XYI10QM
CAS number
15687-27-1
Weight
Average: 206.2808
Monoisotopic: 206.13067982
Chemical Formula
C13H18O2
InChI Key
HEFNNWSXXWATRW-UHFFFAOYSA-N
InChI
InChI=1S/C13H18O2/c1-9(2)8-11-4-6-12(7-5-11)10(3)13(14)15/h4-7,9-10H,8H2,1-3H3,(H,14,15)
IUPAC Name
2-[4-(2-methylpropyl)phenyl]propanoic acid
SMILES
CC(C)CC1=CC=C(C=C1)C(C)C(O)=O

Pharmacology

Indication

For symptomatic treatment of rheumatoid arthritis, juvenile rheumatoid arthritis and osteoarthritis. May be used to treat mild to moderate pain and for the management of dysmenorrhea. May be used to reduce fever. Has been used with some success for treating ankylosing spondylitis, gout and psoriatic arthritis. May reduce pain, fever and inflammation of pericarditis. May be used IV with opiates to relieve moderate to severe pain. Ibuprofen lysine may be used IV to treat patent ductus arteriosus (PDA) in premature neonates.

Associated Conditions
Pharmacodynamics

Ibuprofen is a nonsteroidal anti-inflammatory agent (NSAIA) or nonsteroidal anti-inflammatory drug (NSAID), with analgesic and antipyretic properties. Ibuprofen has pharmacologic actions similar to those of other prototypical NSAIAs, which are thought to act through inhibition of prostaglandin synthesis.

Mechanism of action

The exact mechanism of action of ibuprofen is unknown. Ibuprofen is a non-selective inhibitor of cyclooxygenase, an enzyme invovled in prostaglandin synthesis via the arachidonic acid pathway. Its pharmacological effects are believed to be due to inhibition cylooxygenase-2 (COX-2) which decreases the synthesis of prostaglandins involved in mediating inflammation, pain, fever and swelling. Antipyretic effects may be due to action on the hypothalamus, resulting in an increased peripheral blood flow, vasodilation, and subsequent heat dissipation. Inhibition of COX-1 is thought to cause some of the side effects of ibuprofen including GI ulceration. Ibuprofen is administered as a racemic mixture. The R-enantiomer undergoes extensive interconversion to the S-enantiomer in vivo. The S-enantiomer is believed to be the more pharmacologically active enantiomer.

TargetActionsOrganism
AProstaglandin G/H synthase 2
inhibitor
Human
AProstaglandin G/H synthase 1Not AvailableHuman
UApoptosis regulator Bcl-2
modulator
Human
UThrombomodulin
modulator
Human
UTissue-type plasminogen activator
negative modulator
Human
UFatty acid-binding protein, intestinal
binder
Human
UPeroxisome proliferator-activated receptor gamma
activator
Human
UCystic fibrosis transmembrane conductance regulator
inhibitor
Human
USolute carrier family 15 member 1Not AvailableHuman
UPeroxisome proliferator-activated receptor alpha
activator
Human
Absorption

~ 80% absorbed from GI tract

Time to reach peak plasma concentration = 47 minutes (suspension), 62 minutes (chewable tablets), 120 minutes (conventional tablets)

Volume of distribution
Not Available
Protein binding

90-99% to whole human plasma and site II of purified albumin, binding appears to be saturable and becomes non-linear at concentrations exceeding 20 mcg/ml.

Metabolism

R-enanatiomer undergoes extensive enantiomeric conversion (53-65%) to the more active S-enantiomer in vivo. Metablized by oxidation to 2 inactive metabolites: (+)-2[4´-(2-hydroxy-2-methylpropyl)phenyl]propionic acid and (+)-2-[4´-(2-carboxypropyl)phenyl]propionic acid. Very small amounts of 1-hydroxyibuprofen and 3-hydroxyibuprofen have been recovered from urine. Cytochrome P450 2C9 is the major catalyst in the formation of oxidative metabolites. Oxidative metabolites may be conjugated to glucuronide prior to excretion.

Route of elimination

Ibuprofen is rapidly metabolized and eliminated in the urine.

Half life

2-4 hours

Clearance
Not Available
Toxicity

Side effects: May cause peripheral edema and fluid retention. Use caution in patients with congestive heart failure or severe uncontrolled hypertension. May cause dyspepsia, heartburn, nausea, vomiting, anorexia, diarrhea, constipation, stomatitis, flatulence, bloating, epigastric pain, and abdominal pain. Peptic ulcer and GI bleeding have been reported. May also cause dizziness, headache and nervousness. Acute renal failure accompanied by acute tubular necrosis has been reported.

Most common symptoms of overdose are abdominal pain, nausea, vomiting, lethargy, vertigo, drowsiness (somnolence), dizziness and insomnia. Other symptoms of overdose include headache, loss of consciousness, tinnitus, CNS depression, convulsions and seizures. May rarely cause metabolic acidosis, abnormal hepatic function, hyperkalemia, renal failure, dyspnea, respiratory depression, coma, acute renal failure, and apnea (primarily in very young pediatric patients).

LD50=1255mg/kg(orally in mice)

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Ibuprofen Action PathwayDrug action
Ibuprofen Metabolism PathwayDrug metabolism
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(R)-warfarinThe risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with (R)-warfarin.Experimental
(S)-WarfarinThe risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with (S)-Warfarin.Experimental, Investigational
4-hydroxycoumarinThe risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with 4-hydroxycoumarin.Experimental
AbciximabThe risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with Abciximab.Approved
AbemaciclibThe serum concentration of Abemaciclib can be increased when it is combined with Ibuprofen.Approved, Investigational
AbirateroneThe metabolism of Ibuprofen can be decreased when combined with Abiraterone.Approved
AcebutololIbuprofen may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolThe risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with Acenocoumarol.Approved, Investigational
AcetohexamideThe protein binding of Acetohexamide can be decreased when combined with Ibuprofen.Approved, Investigational, Withdrawn
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Ibuprofen.Approved, Vet Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Ibuprofen.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of gastrointestinal irritation can be increased when Alclometasone is combined with Ibuprofen.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Ibuprofen.Experimental, Investigational
Alendronic acidThe risk or severity of gastrointestinal bleeding can be increased when Ibuprofen is combined with Alendronic acid.Approved
AliskirenThe risk or severity of renal failure and hypertension can be increased when Ibuprofen is combined with Aliskiren.Approved, Investigational
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Ibuprofen.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Alminoprofen.Experimental
AlprenololIbuprofen may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Ibuprofen.Approved, Investigational
AlteplaseThe risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with Alteplase.Approved
AmbrisentanThe therapeutic efficacy of Ambrisentan can be decreased when used in combination with Ibuprofen.Approved, Investigational
AmcinonideThe risk or severity of gastrointestinal irritation can be increased when Amcinonide is combined with Ibuprofen.Approved
AmediplaseThe risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with Amediplase.Investigational
AmikacinThe risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Amikacin.Approved, Investigational, Vet Approved
AmilorideThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuprofen is combined with Amiloride.Approved
AminophenazoneThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Aminophenazone.Approved, Withdrawn
AmiodaroneThe metabolism of Ibuprofen can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Ibuprofen.Approved
AmlodipineThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Ibuprofen.Approved
Amphotericin BThe risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Ibuprofen.Approved, Investigational
AmprenavirThe serum concentration of Amprenavir can be increased when it is combined with Ibuprofen.Approved, Investigational
AnagrelideThe risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with Anagrelide.Approved
AncrodThe risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with Ancrod.Approved, Investigational
AnisodamineIbuprofen may decrease the antihypertensive activities of Anisodamine.Investigational
AnistreplaseThe risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with Anistreplase.Approved
AntipyrineThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Antipyrine.Approved, Investigational
Antithrombin III humanThe risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with Antithrombin III human.Approved
AntrafenineThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Antrafenine.Approved
ApalutamideThe serum concentration of Ibuprofen can be decreased when it is combined with Apalutamide.Approved, Investigational
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Ibuprofen.Approved
ApramycinThe risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Apramycin.Experimental, Vet Approved
AprepitantThe metabolism of Ibuprofen can be increased when combined with Aprepitant.Approved, Investigational
ArbekacinThe risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Arbekacin.Approved, Investigational
ArdeparinThe risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanThe risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with Argatroban.Approved, Investigational
ArotinololIbuprofen may decrease the antihypertensive activities of Arotinolol.Investigational
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Ibuprofen.Approved, Investigational
Ascorbic acidThe serum concentration of Ascorbic acid can be increased when it is combined with Ibuprofen.Approved, Nutraceutical
AstaxanthinThe risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with Astaxanthin.Investigational
AsunaprevirThe serum concentration of Asunaprevir can be increased when it is combined with Ibuprofen.Approved, Investigational, Withdrawn
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Ibuprofen.Approved, Investigational
AtenololIbuprofen may decrease the antihypertensive activities of Atenolol.Approved
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Ibuprofen.Approved
AvatrombopagThe serum concentration of Avatrombopag can be increased when it is combined with Ibuprofen.Approved, Investigational
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Ibuprofen.Approved, Investigational
AzapropazoneThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Azapropazone.Withdrawn
Azilsartan medoxomilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Azilsartan medoxomil is combined with Ibuprofen.Approved, Investigational
AzosemideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Ibuprofen.Investigational
BacitracinThe risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Bacitracin.Approved, Vet Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Ibuprofen.Approved, Investigational
BaricitinibThe serum concentration of Baricitinib can be increased when it is combined with Ibuprofen.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of gastrointestinal irritation can be increased when Beclomethasone dipropionate is combined with Ibuprofen.Approved, Investigational
BefunololIbuprofen may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinThe risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Bekanamycin.Experimental
BelinostatThe serum concentration of Belinostat can be increased when it is combined with Ibuprofen.Approved, Investigational
BemiparinThe risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with Bemiparin.Approved, Investigational
BenazeprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuprofen is combined with Benazepril.Approved, Investigational
BenazeprilatThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuprofen is combined with Benazeprilat.Experimental
BendazacThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Ibuprofen.Approved
BenorilateThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Benoxaprofen.Withdrawn
BenzthiazideThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Ibuprofen.Approved
BenzydamineThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Benzydamine.Approved
BepridilThe therapeutic efficacy of Bepridil can be decreased when used in combination with Ibuprofen.Approved, Withdrawn
BeraprostThe risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with Beraprost.Investigational
BesifloxacinIbuprofen may increase the neuroexcitatory activities of Besifloxacin.Approved
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Ibuprofen.Approved, Vet Approved
BetaxololIbuprofen may decrease the antihypertensive activities of Betaxolol.Approved, Investigational
BethanidineThe therapeutic efficacy of Bethanidine can be decreased when used in combination with Ibuprofen.Approved
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Ibuprofen.Approved, Investigational
BevantololIbuprofen may decrease the antihypertensive activities of Bevantolol.Approved
BietaserpineThe therapeutic efficacy of Bietaserpine can be decreased when used in combination with Ibuprofen.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Ibuprofen.Approved, Investigational
BisoprololIbuprofen may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinThe risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with Bivalirudin.Approved, Investigational
BopindololIbuprofen may decrease the antihypertensive activities of Bopindolol.Approved
BosentanThe therapeutic efficacy of Bosentan can be decreased when used in combination with Ibuprofen.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Ibuprofen.Approved
BQ-123The therapeutic efficacy of BQ-123 can be decreased when used in combination with Ibuprofen.Investigational
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Ibuprofen.Approved, Investigational
BretyliumThe therapeutic efficacy of Bretylium can be decreased when used in combination with Ibuprofen.Approved
BrimonidineThe therapeutic efficacy of Brimonidine can be decreased when used in combination with Ibuprofen.Approved
BrinaseThe risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with Brinase.Experimental
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Ibuprofen.Approved
BromperidolThe serum concentration of Bromperidol can be increased when it is combined with Ibuprofen.Approved, Investigational
BucindololIbuprofen may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Ibuprofen.Approved
BufexamacThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Bufexamac.Approved, Experimental
BufuralolIbuprofen may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Bumadizone.Experimental
BumetanideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Ibuprofen.Approved
BupranololIbuprofen may decrease the antihypertensive activities of Bupranolol.Approved
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Ibuprofen.Approved
CadralazineThe therapeutic efficacy of Cadralazine can be decreased when used in combination with Ibuprofen.Experimental
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Ibuprofen.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Ibuprofen.Approved
CandesartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Candesartan is combined with Ibuprofen.Experimental
Candesartan cilexetilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Candesartan cilexetil is combined with Ibuprofen.Approved
CandoxatrilThe therapeutic efficacy of Candoxatril can be decreased when used in combination with Ibuprofen.Experimental
CangrelorThe risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with Cangrelor.Approved
CapecitabineThe metabolism of Ibuprofen can be decreased when combined with Capecitabine.Approved, Investigational
CapreomycinThe risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Capreomycin.Approved
CaptoprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuprofen is combined with Captopril.Approved
CarbamazepineThe serum concentration of Ibuprofen can be decreased when it is combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Carbaspirin calcium.Experimental, Investigational
CarboplatinThe risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Carboplatin.Approved
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Ibuprofen.Approved
CarbutamideThe protein binding of Carbutamide can be decreased when combined with Ibuprofen.Experimental
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Ibuprofen.Approved, Investigational
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Ibuprofen.Approved, Vet Approved, Withdrawn
CarteololIbuprofen may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolIbuprofen may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CefacetrileThe risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Cefacetrile.Approved
CefaclorThe risk or severity of nephrotoxicity can be increased when Cefaclor is combined with Ibuprofen.Approved
CefadroxilThe risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Cefadroxil.Approved, Vet Approved, Withdrawn
CefalotinThe risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Cefalotin.Approved, Investigational, Vet Approved
CefamandoleThe risk or severity of nephrotoxicity can be increased when Cefamandole is combined with Ibuprofen.Approved, Investigational
CefapirinThe risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Cefapirin.Approved, Vet Approved
CefatrizineThe risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Cefatrizine.Experimental
CefazedoneThe risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Cefazedone.Experimental
CefazolinThe risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Cefazolin.Approved
CefbuperazoneThe risk or severity of nephrotoxicity can be increased when Cefbuperazone is combined with Ibuprofen.Experimental
CefcapeneThe risk or severity of nephrotoxicity can be increased when Cefcapene is combined with Ibuprofen.Experimental
CefditorenThe risk or severity of nephrotoxicity can be increased when Cefditoren is combined with Ibuprofen.Approved, Investigational
CefepimeThe risk or severity of nephrotoxicity can be increased when Cefepime is combined with Ibuprofen.Approved, Investigational
CefetametThe risk or severity of nephrotoxicity can be increased when Cefetamet is combined with Ibuprofen.Experimental
CefmenoximeThe risk or severity of nephrotoxicity can be increased when Cefmenoxime is combined with Ibuprofen.Approved
CefmetazoleThe risk or severity of nephrotoxicity can be increased when Cefmetazole is combined with Ibuprofen.Approved, Investigational
CefminoxThe risk or severity of nephrotoxicity can be increased when Cefminox is combined with Ibuprofen.Approved
CefodizimeThe risk or severity of nephrotoxicity can be increased when Cefodizime is combined with Ibuprofen.Experimental
CefonicidThe risk or severity of nephrotoxicity can be increased when Cefonicid is combined with Ibuprofen.Approved, Investigational
CefoperazoneThe risk or severity of nephrotoxicity can be increased when Cefoperazone is combined with Ibuprofen.Approved, Investigational
CeforanideThe risk or severity of nephrotoxicity can be increased when Ceforanide is combined with Ibuprofen.Approved
CefotaximeThe risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Ibuprofen.Approved
CefotetanThe risk or severity of nephrotoxicity can be increased when Cefotetan is combined with Ibuprofen.Approved
CefotiamThe risk or severity of nephrotoxicity can be increased when Cefotiam is combined with Ibuprofen.Approved, Investigational
CefoxitinThe risk or severity of nephrotoxicity can be increased when Cefoxitin is combined with Ibuprofen.Approved
CefozopranThe risk or severity of nephrotoxicity can be increased when Cefozopran is combined with Ibuprofen.Experimental
CefpiramideThe risk or severity of nephrotoxicity can be increased when Cefpiramide is combined with Ibuprofen.Approved
CefpiromeThe risk or severity of nephrotoxicity can be increased when Cefpirome is combined with Ibuprofen.Approved
CefpodoximeThe risk or severity of nephrotoxicity can be increased when Cefpodoxime is combined with Ibuprofen.Approved, Vet Approved
CefprozilThe risk or severity of nephrotoxicity can be increased when Cefprozil is combined with Ibuprofen.Approved
CefradineThe risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Cefradine.Approved
CefroxadineThe risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Cefroxadine.Withdrawn
CefsulodinThe risk or severity of nephrotoxicity can be increased when Cefsulodin is combined with Ibuprofen.Experimental
Ceftaroline fosamilThe risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Ceftaroline fosamil.Approved, Investigational
CeftazidimeThe risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Ibuprofen.Approved
CeftezoleThe risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Ceftezole.Experimental
CeftibutenThe risk or severity of nephrotoxicity can be increased when Ceftibuten is combined with Ibuprofen.Approved, Investigational
CeftizoximeThe risk or severity of nephrotoxicity can be increased when Ceftizoxime is combined with Ibuprofen.Approved, Investigational
CeftobiproleThe risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Ceftobiprole.Approved, Investigational
CeftriaxoneThe risk or severity of nephrotoxicity can be increased when Ceftriaxone is combined with Ibuprofen.Approved
CefuroximeThe risk or severity of nephrotoxicity can be increased when Cefuroxime is combined with Ibuprofen.Approved
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Ibuprofen.Approved, Investigational
CeliprololIbuprofen may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CephalexinThe risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Cephalexin.Approved, Investigational, Vet Approved
CephaloglycinThe risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Cephaloglycin.Approved
CephaloridineThe risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Cephaloridine.Approved, Withdrawn
Cephalothin GroupThe risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Cephalothin Group.Experimental
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Ibuprofen.Approved, Withdrawn
Cerliponase alfaThe serum concentration of Cerliponase alfa can be increased when it is combined with Ibuprofen.Approved, Investigational
CertoparinThe risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with Certoparin.Approved, Investigational
ChlorambucilThe serum concentration of Chlorambucil can be increased when it is combined with Ibuprofen.Approved
ChloroquineThe serum concentration of Chloroquine can be increased when it is combined with Ibuprofen.Approved, Investigational, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Ibuprofen.Approved, Vet Approved
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Ibuprofen.Approved, Investigational, Vet Approved
ChlorpropamideThe protein binding of Chlorpropamide can be decreased when combined with Ibuprofen.Approved, Investigational
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Ibuprofen.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Ibuprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Choline magnesium trisalicylate.Approved
CiclesonideThe risk or severity of gastrointestinal irritation can be increased when Ciclesonide is combined with Ibuprofen.Approved, Investigational
CicletanineThe therapeutic efficacy of Cicletanine can be decreased when used in combination with Ibuprofen.Investigational
CilazaprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuprofen is combined with Cilazapril.Approved
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Ibuprofen.Approved, Investigational
CimicoxibThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Cimicoxib.Investigational
CinoxacinIbuprofen may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Ibuprofen.Approved, Investigational
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Ibuprofen.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Ibuprofen.Approved
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Ibuprofen.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Ibuprofen.Approved, Illicit
ClobetasolThe risk or severity of gastrointestinal irritation can be increased when Clobetasol is combined with Ibuprofen.Approved, Investigational
Clobetasol propionateThe risk or severity of gastrointestinal irritation can be increased when Clobetasol propionate is combined with Ibuprofen.Approved
ClobetasoneThe risk or severity of gastrointestinal irritation can be increased when Clobetasone is combined with Ibuprofen.Approved
ClocortoloneThe risk or severity of gastrointestinal irritation can be increased when Clocortolone is combined with Ibuprofen.Approved
Clodronic AcidThe risk or severity of gastrointestinal bleeding can be increased when Ibuprofen is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonidineThe therapeutic efficacy of Clonidine can be decreased when used in combination with Ibuprofen.Approved
ClonixinThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Clonixin.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Ibuprofen.Approved
CloprednolThe risk or severity of gastrointestinal irritation can be increased when Cloprednol is combined with Ibuprofen.Experimental
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Ibuprofen.Vet Approved
CloranololIbuprofen may decrease the antihypertensive activities of Cloranolol.Experimental
ClorindioneThe risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with Clorindione.Experimental
ClotrimazoleThe metabolism of Ibuprofen can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Ibuprofen.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Ibuprofen.Approved, Investigational
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Ibuprofen.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Ibuprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Ibuprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColistimethateThe risk or severity of nephrotoxicity can be increased when Colistimethate is combined with Ibuprofen.Approved, Vet Approved
Conjugated estrogensThe serum concentration of Conjugated estrogens can be increased when it is combined with Ibuprofen.Approved
CopanlisibThe serum concentration of Copanlisib can be increased when it is combined with Ibuprofen.Approved, Investigational
CorticotropinThe risk or severity of gastrointestinal irritation can be increased when Corticotropin is combined with Ibuprofen.Approved, Investigational, Vet Approved
Cortisone acetateThe risk or severity of gastrointestinal irritation can be increased when Cortisone acetate is combined with Ibuprofen.Approved, Investigational
CortivazolThe risk or severity of gastrointestinal irritation can be increased when Cortivazol is combined with Ibuprofen.Investigational
CrisaboroleThe metabolism of Ibuprofen can be decreased when combined with Crisaborole.Approved, Investigational
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Ibuprofen.Approved
CryptenamineThe therapeutic efficacy of Cryptenamine can be decreased when used in combination with Ibuprofen.Approved
CurcuminThe metabolism of Ibuprofen can be decreased when combined with Curcumin.Approved, Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Ibuprofen.Experimental
CyclosporineThe risk or severity of renal failure and hypertension can be increased when Ibuprofen is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideThe therapeutic efficacy of Cyclothiazide can be decreased when used in combination with Ibuprofen.Approved
CytarabineThe serum concentration of Cytarabine can be increased when it is combined with Ibuprofen.Approved, Investigational
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Ibuprofen.Approved
DabrafenibThe serum concentration of Ibuprofen can be decreased when it is combined with Dabrafenib.Approved, Investigational
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Ibuprofen.Approved, Investigational
DalteparinThe risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with Dalteparin.Approved
DanaparoidThe risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with Danaparoid.Approved, Withdrawn
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Ibuprofen.Approved
DarexabanThe risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with Darexaban.Investigational
DasabuvirThe serum concentration of Dasabuvir can be increased when it is combined with Ibuprofen.Approved
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Ibuprofen.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Ibuprofen.Approved
DebrisoquinThe therapeutic efficacy of Debrisoquin can be decreased when used in combination with Ibuprofen.Approved, Investigational
DeferasiroxThe risk or severity of gastrointestinal bleeding and peptic ulcer can be increased when Ibuprofen is combined with Deferasirox.Approved, Investigational
DefibrotideThe risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with Defibrotide.Approved, Investigational
DeflazacortThe risk or severity of gastrointestinal irritation can be increased when Deflazacort is combined with Ibuprofen.Approved, Investigational
DelaprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuprofen is combined with Delapril.Investigational
DelavirdineThe metabolism of Ibuprofen can be decreased when combined with Delavirdine.Approved
DeserpidineThe therapeutic efficacy of Deserpidine can be decreased when used in combination with Ibuprofen.Approved
DesirudinThe risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with Desirudin.Approved
DesmopressinThe risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Ibuprofen is combined with Desmopressin.Approved
DesmoteplaseThe risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with Desmoteplase.Investigational
DesonideThe risk or severity of gastrointestinal irritation can be increased when Desonide is combined with Ibuprofen.Approved, Investigational
DesoximetasoneThe risk or severity of gastrointestinal irritation can be increased when Desoximetasone is combined with Ibuprofen.Approved
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Ibuprofen.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone isonicotinate is combined with Ibuprofen.Vet Approved
DexibuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Dexibuprofen.Approved, Investigational
DexketoprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Dexketoprofen.Approved, Investigational
DexniguldipineThe therapeutic efficacy of Dexniguldipine can be decreased when used in combination with Ibuprofen.Experimental
DextranThe risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with Dextran.Approved, Investigational, Vet Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Ibuprofen.Approved, Illicit, Investigational, Vet Approved
DiazoxideThe therapeutic efficacy of Diazoxide can be decreased when used in combination with Ibuprofen.Approved
DibekacinThe risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Dibekacin.Experimental
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Ibuprofen.Approved, Vet Approved
DicoumarolThe risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with Dicoumarol.Approved
DiethylnorspermineThe therapeutic efficacy of Diethylnorspermine can be decreased when used in combination with Ibuprofen.Investigational
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Ibuprofen.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of gastrointestinal irritation can be increased when Diflorasone is combined with Ibuprofen.Approved
DifloxacinIbuprofen may increase the neuroexcitatory activities of Difloxacin.Vet Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Ibuprofen.Approved, Investigational
DifluocortoloneThe risk or severity of gastrointestinal irritation can be increased when Difluocortolone is combined with Ibuprofen.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of gastrointestinal irritation can be increased when Difluprednate is combined with Ibuprofen.Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Ibuprofen.Approved, Investigational
DigoxinIbuprofen may decrease the excretion rate of Digoxin which could result in a higher serum level.Approved
DihydralazineThe therapeutic efficacy of Dihydralazine can be decreased when used in combination with Ibuprofen.Approved, Investigational
DihydrostreptomycinThe risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Dihydrostreptomycin.Investigational, Vet Approved
DiltiazemThe therapeutic efficacy of Diltiazem can be decreased when used in combination with Ibuprofen.Approved, Investigational
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Ibuprofen.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Ibuprofen.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Ibuprofen.Approved
DiphenadioneThe risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with Diphenadione.Experimental
DipyridamoleThe risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with Dipyridamole.Approved
DitazoleThe risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with Ditazole.Approved, Withdrawn
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Ibuprofen.Approved, Investigational
DolutegravirThe serum concentration of Dolutegravir can be increased when it is combined with Ibuprofen.Approved
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Ibuprofen.Approved, Investigational, Vet Approved
DorzolamideThe therapeutic efficacy of Dorzolamide can be decreased when used in combination with Ibuprofen.Approved
DoxazosinThe therapeutic efficacy of Doxazosin can be decreased when used in combination with Ibuprofen.Approved
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Ibuprofen.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Ibuprofen.Approved, Investigational
DoxycyclineThe serum concentration of Doxycycline can be increased when it is combined with Ibuprofen.Approved, Investigational, Vet Approved
DrospirenoneThe risk or severity of hyperkalemia can be increased when Ibuprofen is combined with Drospirenone.Approved
Drotrecogin alfaThe risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with Drotrecogin alfa.Approved, Investigational, Withdrawn
DroxicamThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Droxicam.Withdrawn
Edetic AcidThe risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with Edetic Acid.Approved, Vet Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Ibuprofen.Approved
EfavirenzThe serum concentration of Ibuprofen can be decreased when it is combined with Efavirenz.Approved, Investigational
EfonidipineThe therapeutic efficacy of Efonidipine can be decreased when used in combination with Ibuprofen.Approved, Investigational
ElagolixThe serum concentration of Elagolix can be increased when it is combined with Ibuprofen.Approved, Investigational
ElbasvirThe serum concentration of Elbasvir can be increased when it is combined with Ibuprofen.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Ibuprofen.Approved, Investigational
EnalaprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuprofen is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuprofen is combined with Enalaprilat.Approved
EndralazineThe therapeutic efficacy of Endralazine can be decreased when used in combination with Ibuprofen.Experimental
EnoxacinIbuprofen may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinThe risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Ibuprofen.Experimental
EpanololIbuprofen may decrease the antihypertensive activities of Epanolol.Experimental
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Ibuprofen.Approved, Investigational
EpirizoleThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Epirizole.Approved
EpitizideThe therapeutic efficacy of Epitizide can be decreased when used in combination with Ibuprofen.Experimental
EplerenoneThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuprofen is combined with Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Ibuprofen.Approved
EprosartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Eprosartan is combined with Ibuprofen.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Ibuprofen.Approved, Investigational
ErtugliflozinThe serum concentration of Ertugliflozin can be increased when it is combined with Ibuprofen.Approved, Investigational
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Ibuprofen.Approved, Investigational, Vet Approved
EsatenololIbuprofen may decrease the antihypertensive activities of Esatenolol.Experimental
EsmololIbuprofen may decrease the antihypertensive activities of Esmolol.Approved
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Ibuprofen.Approved, Investigational, Vet Approved
Estradiol acetateThe serum concentration of Estradiol acetate can be increased when it is combined with Ibuprofen.Approved, Investigational, Vet Approved
Estradiol benzoateThe serum concentration of Estradiol benzoate can be increased when it is combined with Ibuprofen.Approved, Investigational, Vet Approved
Estradiol cypionateThe serum concentration of Estradiol cypionate can be increased when it is combined with Ibuprofen.Approved, Investigational, Vet Approved
Estradiol dienanthateThe serum concentration of Estradiol dienanthate can be increased when it is combined with Ibuprofen.Approved, Investigational, Vet Approved
Estradiol valerateThe serum concentration of Estradiol valerate can be increased when it is combined with Ibuprofen.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Ibuprofen.Approved, Investigational, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Ibuprofen.Approved
Etacrynic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Ibuprofen.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Ethenzamide.Experimental
Ethinyl EstradiolThe serum concentration of Ibuprofen can be decreased when it is combined with Ethinyl Estradiol.Approved
Ethyl biscoumacetateThe risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of gastrointestinal bleeding can be increased when Ibuprofen is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Ibuprofen.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Etofenamate.Approved, Investigational
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Ibuprofen.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Etoricoxib.Approved, Investigational
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Ibuprofen.Approved
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Ibuprofen.Approved
FelbamateThe metabolism of Ibuprofen can be decreased when combined with Felbamate.Approved
FelbinacThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Felbinac.Experimental
FelodipineThe therapeutic efficacy of Felodipine can be decreased when used in combination with Ibuprofen.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Fenbufen.Approved
FenoldopamThe therapeutic efficacy of Fenoldopam can be decreased when used in combination with Ibuprofen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Ibuprofen.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Ibuprofen.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Feprazone.Experimental
Ferulic acidThe therapeutic efficacy of Ferulic acid can be decreased when used in combination with Ibuprofen.Experimental
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Ibuprofen.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Ibuprofen.Approved, Investigational
FibrinolysinThe risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with Fibrinolysin.Investigational
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Ibuprofen.Approved
FimasartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Ibuprofen.Approved, Investigational
FirocoxibThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Firocoxib.Experimental, Vet Approved
FleroxacinIbuprofen may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Floctafenine.Approved, Withdrawn
FlomoxefThe risk or severity of nephrotoxicity can be increased when Flomoxef is combined with Ibuprofen.Investigational
FloxuridineThe metabolism of Ibuprofen can be decreased when combined with Floxuridine.Approved
Fluciclovine (18F)The serum concentration of Fluciclovine (18F) can be increased when it is combined with Ibuprofen.Approved
FlucloroloneThe risk or severity of gastrointestinal irritation can be increased when Fluclorolone is combined with Ibuprofen.Experimental
FluconazoleThe metabolism of Ibuprofen can be decreased when combined with Fluconazole.Approved, Investigational
FludrocortisoneThe risk or severity of gastrointestinal irritation can be increased when Fludrocortisone is combined with Ibuprofen.Approved, Investigational
FluindioneThe risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with Fluindione.Approved, Investigational
FlumequineIbuprofen may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of gastrointestinal irritation can be increased when Flumethasone is combined with Ibuprofen.Approved, Vet Approved
FlunisolideThe risk or severity of gastrointestinal irritation can be increased when Flunisolide is combined with Ibuprofen.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of gastrointestinal irritation can be increased when Fluocinolone Acetonide is combined with Ibuprofen.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of gastrointestinal irritation can be increased when Fluocinonide is combined with Ibuprofen.Approved, Investigational
FluocortinThe risk or severity of gastrointestinal irritation can be increased when Fluocortin is combined with Ibuprofen.Experimental
FluocortoloneThe risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Ibuprofen.Approved, Withdrawn
FluorometholoneThe risk or severity of gastrointestinal irritation can be increased when Fluorometholone is combined with Ibuprofen.Approved, Investigational
FluorouracilThe metabolism of Ibuprofen can be decreased when combined with Fluorouracil.Approved
FluoxetineThe metabolism of Ibuprofen can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Flupentixol can be increased when it is combined with Ibuprofen.Approved, Investigational, Withdrawn
FluperoloneThe risk or severity of gastrointestinal irritation can be increased when Fluperolone is combined with Ibuprofen.Experimental
FluprednideneThe risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Ibuprofen.Approved, Withdrawn
FluprednisoloneThe risk or severity of gastrointestinal irritation can be increased when Fluprednisolone is combined with Ibuprofen.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Ibuprofen.Vet Approved
FlurandrenolideThe risk or severity of gastrointestinal irritation can be increased when Flurandrenolide is combined with Ibuprofen.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Ibuprofen.Approved, Investigational
FluticasoneThe serum concentration of Fluticasone can be increased when it is combined with Ibuprofen.Approved, Experimental, Investigational
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Ibuprofen.Approved
Fluticasone propionateThe serum concentration of Fluticasone propionate can be increased when it is combined with Ibuprofen.Approved
FluvoxamineThe metabolism of Ibuprofen can be decreased when combined with Fluvoxamine.Approved, Investigational
FondaparinuxThe risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with Fondaparinux.Approved, Investigational
ForasartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Forasartan is combined with Ibuprofen.Experimental
FormocortalThe risk or severity of gastrointestinal irritation can be increased when Formocortal is combined with Ibuprofen.Experimental
FoscarnetThe risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Foscarnet.Approved
FosinoprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuprofen is combined with Fosinopril.Approved
FosinoprilatThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuprofen is combined with Fosinoprilat.Experimental
FosphenytoinThe metabolism of Ibuprofen can be increased when combined with Fosphenytoin.Approved, Investigational
FramycetinThe risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Framycetin.Approved
FurosemideThe therapeutic efficacy of Furosemide can be decreased when used in combination with Ibuprofen.Approved, Vet Approved
GabexateThe risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with Gabexate.Investigational
GarenoxacinIbuprofen may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinIbuprofen may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Ibuprofen.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Ibuprofen.Approved, Withdrawn
GemfibrozilThe metabolism of Ibuprofen can be decreased when combined with Gemfibrozil.Approved
GemifloxacinIbuprofen may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinThe risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Geneticin.Experimental
GentamicinThe risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Gentamicin.Approved, Vet Approved
GENTAMICIN C1AThe risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with GENTAMICIN C1A.Experimental
GlecaprevirThe serum concentration of Glecaprevir can be increased when it is combined with Ibuprofen.Approved, Investigational
GliclazideThe protein binding of Gliclazide can be decreased when combined with Ibuprofen.Approved
GlipizideThe protein binding of Glipizide can be decreased when combined with Ibuprofen.Approved, Investigational
GlyburideThe protein binding of Glyburide can be decreased when combined with Ibuprofen.Approved
Gramicidin DThe serum concentration of Gramicidin D can be increased when it is combined with Ibuprofen.Approved
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Ibuprofen.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Ibuprofen.Approved, Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Guacetisal.Experimental
GuanabenzThe therapeutic efficacy of Guanabenz can be decreased when used in combination with Ibuprofen.Approved, Investigational
GuanadrelThe therapeutic efficacy of Guanadrel can be decreased when used in combination with Ibuprofen.Approved
GuanazodineThe therapeutic efficacy of Guanazodine can be decreased when used in combination with Ibuprofen.Experimental
GuanethidineThe therapeutic efficacy of Guanethidine can be decreased when used in combination with Ibuprofen.Approved
GuanfacineThe therapeutic efficacy of Guanfacine can be decreased when used in combination with Ibuprofen.Approved, Investigational
GuanoclorThe therapeutic efficacy of Guanoclor can be decreased when used in combination with Ibuprofen.Experimental
GuanoxabenzThe therapeutic efficacy of Guanoxabenz can be decreased when used in combination with Ibuprofen.Experimental
GuanoxanThe therapeutic efficacy of Guanoxan can be decreased when used in combination with Ibuprofen.Experimental
HalcinonideThe risk or severity of gastrointestinal irritation can be increased when Halcinonide is combined with Ibuprofen.Approved, Investigational, Withdrawn
HalometasoneThe risk or severity of gastrointestinal irritation can be increased when Halometasone is combined with Ibuprofen.Experimental
HaloperidolThe therapeutic efficacy of Haloperidol can be increased when used in combination with Ibuprofen.Approved
HeparinThe risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with Heparin.Approved, Investigational
HexamethoniumThe therapeutic efficacy of Hexamethonium can be decreased when used in combination with Ibuprofen.Experimental
HydralazineIbuprofen may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Ibuprofen.Approved, Vet Approved
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Ibuprofen.Approved, Vet Approved
Hydrocortisone aceponateThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone aceponate is combined with Ibuprofen.Experimental, Vet Approved
Hydrocortisone acetateThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone acetate is combined with Ibuprofen.Approved, Vet Approved
Hydrocortisone butyrateThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone butyrate is combined with Ibuprofen.Approved, Vet Approved
Hydrocortisone probutateThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone probutate is combined with Ibuprofen.Approved, Vet Approved
Hydrocortisone succinateThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone succinate is combined with Ibuprofen.Approved
Hydrocortisone valerateThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone valerate is combined with Ibuprofen.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Ibuprofen.Approved, Investigational
Hydrolyzed CephalothinThe risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Hydrolyzed Cephalothin.Experimental
HydroxyureaThe serum concentration of Hydroxyurea can be increased when it is combined with Ibuprofen.Approved
Hygromycin BThe risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Hygromycin B.Vet Approved
IbandronateThe risk or severity of gastrointestinal bleeding can be increased when Ibuprofen is combined with Ibandronate.Approved, Investigational
IbuproxamThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Ibuproxam.Withdrawn
IcosapentThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Icosapent.Approved, Nutraceutical
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Ibuprofen.Approved
IdraparinuxThe risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with Idraparinux.Investigational
IloprostThe risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with Iloprost.Approved, Investigational
ImatinibThe serum concentration of Imatinib can be decreased when it is combined with Ibuprofen.Approved
ImidaprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuprofen is combined with Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Imidazole salicylate.Experimental
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Ibuprofen.Approved
Incadronic acidThe risk or severity of gastrointestinal bleeding can be increased when Ibuprofen is combined with Incadronic acid.Approved, Investigational
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Ibuprofen.Approved
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Ibuprofen.Approved
IndenololIbuprofen may decrease the antihypertensive activities of Indenolol.Withdrawn
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Ibuprofen.Approved
IndobufenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Ibuprofen.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Indoprofen.Withdrawn
IndoraminThe therapeutic efficacy of Indoramin can be decreased when used in combination with Ibuprofen.Withdrawn
Inotuzumab ozogamicinThe serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Ibuprofen.Approved, Investigational
IrbesartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Irbesartan is combined with Ibuprofen.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Ibuprofen.Approved, Investigational
IsepamicinThe risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Isepamicin.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Isoxicam.Withdrawn
IsradipineThe therapeutic efficacy of Isradipine can be decreased when used in combination with Ibuprofen.Approved, Investigational
ItraconazoleThe serum concentration of Itraconazole can be increased when it is combined with Ibuprofen.Approved, Investigational
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Ibuprofen.Approved, Investigational, Vet Approved
IvosidenibThe serum concentration of Ivosidenib can be increased when it is combined with Ibuprofen.Approved, Investigational
KanamycinThe risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Kanamycin.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Kebuzone.Experimental
KetanserinThe therapeutic efficacy of Ketanserin can be decreased when used in combination with Ibuprofen.Investigational
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Ibuprofen.Approved
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Ibuprofen.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Ibuprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Ibuprofen.Approved
LabetalolIbuprofen may decrease the antihypertensive activities of Labetalol.Approved
LacidipineThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Ibuprofen.Approved, Investigational
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Ibuprofen.Approved, Investigational
LamotrigineThe serum concentration of Ibuprofen can be decreased when it is combined with Lamotrigine.Approved, Investigational
LandiololIbuprofen may decrease the antihypertensive activities of Landiolol.Investigational
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Ibuprofen.Approved, Investigational
LatamoxefThe risk or severity of nephrotoxicity can be increased when Latamoxef is combined with Ibuprofen.Approved, Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Ibuprofen.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Ibuprofen.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Ibuprofen.Approved
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Ibuprofen.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Ibuprofen.Approved, Investigational
LepirudinThe risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with Lepirudin.Approved
LercanidipineThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Ibuprofen.Approved, Investigational
LetaxabanThe risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with Letaxaban.Investigational
LetermovirThe serum concentration of Letermovir can be increased when it is combined with Ibuprofen.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Ibuprofen.Approved, Investigational
LevobetaxololIbuprofen may decrease the antihypertensive activities of Levobetaxolol.Approved, Investigational
LevobunololIbuprofen may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Ibuprofen.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Ibuprofen.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Ibuprofen.Approved, Investigational
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Ibuprofen.Approved
LinsidomineThe therapeutic efficacy of Linsidomine can be decreased when used in combination with Ibuprofen.Experimental
LisinoprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuprofen is combined with Lisinopril.Approved, Investigational
Lithium cationIbuprofen may decrease the excretion rate of Lithium cation which could result in a higher serum level.Experimental
LofexidineThe therapeutic efficacy of Lofexidine can be decreased when used in combination with Ibuprofen.Approved, Investigational
LomefloxacinIbuprofen may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Lonazolac.Experimental
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Ibuprofen.Approved
LoracarbefThe risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Ibuprofen.Investigational, Withdrawn
LornoxicamThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Lornoxicam.Approved, Investigational
LosartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Ibuprofen.Approved
LoteprednolThe risk or severity of gastrointestinal irritation can be increased when Loteprednol is combined with Ibuprofen.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Ibuprofen.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Loxoprofen.Approved, Investigational
LumacaftorThe serum concentration of Ibuprofen can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Ibuprofen.Vet Approved
MacitentanThe therapeutic efficacy of Macitentan can be decreased when used in combination with Ibuprofen.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Magnesium salicylate.Approved
ManidipineThe therapeutic efficacy of Manidipine can be decreased when used in combination with Ibuprofen.Approved, Investigational
MannitolThe risk or severity of nephrotoxicity can be increased when Mannitol is combined with Ibuprofen.Approved, Investigational
MecamylamineThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Ibuprofen.Approved, Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Ibuprofen.Approved, Vet Approved
MedrysoneThe risk or severity of gastrointestinal irritation can be increased when Medrysone is combined with Ibuprofen.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Ibuprofen.Approved
MefloquineThe serum concentration of Mefloquine can be increased when it is combined with Ibuprofen.Approved, Investigational
MelagatranThe risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with Melagatran.Experimental
MelengestrolThe risk or severity of gastrointestinal irritation can be increased when Melengestrol is combined with Ibuprofen.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Ibuprofen.Approved, Vet Approved
MelphalanThe serum concentration of Melphalan can be increased when it is combined with Ibuprofen.Approved
MepindololIbuprofen may decrease the antihypertensive activities of Mepindolol.Experimental
MeprednisoneThe risk or severity of gastrointestinal irritation can be increased when Meprednisone is combined with Ibuprofen.Approved, Investigational
MesalazineThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Metamizole.Approved, Investigational, Withdrawn
MethoserpidineThe therapeutic efficacy of Methoserpidine can be decreased when used in combination with Ibuprofen.Experimental
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Ibuprofen.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Ibuprofen.Approved
MethyldopaThe therapeutic efficacy of Methyldopa can be decreased when used in combination with Ibuprofen.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Ibuprofen.Approved, Vet Approved
MetipranololIbuprofen may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Ibuprofen.Approved
MetoprololIbuprofen may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetyrosineThe therapeutic efficacy of Metyrosine can be decreased when used in combination with Ibuprofen.Approved
MibefradilThe therapeutic efficacy of Mibefradil can be decreased when used in combination with Ibuprofen.Investigational, Withdrawn
MiconazoleThe metabolism of Ibuprofen can be decreased when combined with Miconazole.Approved, Investigational, Vet Approved
MicronomicinThe risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Micronomicin.Experimental
MidostaurinThe metabolism of Ibuprofen can be decreased when combined with Midostaurin.Approved, Investigational
MifamurtideThe therapeutic efficacy of Mifamurtide can be decreased when used in combination with Ibuprofen.Approved, Experimental
MifepristoneThe serum concentration of Ibuprofen can be increased when it is combined with Mifepristone.Approved, Investigational
MinoxidilThe therapeutic efficacy of Minoxidil can be decreased when used in combination with Ibuprofen.Approved, Investigational
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Ibuprofen.Approved
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Ibuprofen.Approved
MitomycinThe serum concentration of Mitomycin can be increased when it is combined with Ibuprofen.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Ibuprofen.Approved, Investigational
MoexiprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuprofen is combined with Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of gastrointestinal irritation can be increased when Mometasone is combined with Ibuprofen.Approved, Vet Approved
Mometasone furoateThe risk or severity of gastrointestinal irritation can be increased when Mometasone furoate is combined with Ibuprofen.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Morniflumate.Approved
MorphineThe serum concentration of Morphine can be increased when it is combined with Ibuprofen.Approved, Investigational
MoxidectinThe serum concentration of Moxidectin can be increased when it is combined with Ibuprofen.Approved, Investigational, Vet Approved
MoxifloxacinIbuprofen may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
MoxonidineThe therapeutic efficacy of Moxonidine can be decreased when used in combination with Ibuprofen.Approved, Investigational
MuzolimineThe therapeutic efficacy of Muzolimine can be decreased when used in combination with Ibuprofen.Experimental
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Ibuprofen.Approved, Investigational
NabiloneThe metabolism of Ibuprofen can be decreased when combined with Nabilone.Approved, Investigational
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Ibuprofen.Approved
NadololIbuprofen may decrease the antihypertensive activities of Nadolol.Approved
NadroparinThe risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with Nadroparin.Approved, Investigational
NafamostatThe risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with Nafamostat.Approved, Investigational
NaftopidilThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Ibuprofen.Investigational
Nalidixic AcidIbuprofen may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Ibuprofen.Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Ibuprofen.Approved, Vet Approved
NeamineThe risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Neamine.Experimental
NebivololIbuprofen may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NelfinavirThe serum concentration of Ibuprofen can be decreased when it is combined with Nelfinavir.Approved
NemonoxacinIbuprofen may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinThe risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Neomycin.Approved, Vet Approved
NeostigmineThe serum concentration of Neostigmine can be increased when it is combined with Ibuprofen.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Ibuprofen.Approved, Investigational
NetilmicinThe risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Netilmicin.Approved, Investigational
NicardipineThe metabolism of Ibuprofen can be decreased when combined with Nicardipine.Approved, Investigational
NicorandilThe therapeutic efficacy of Nicorandil can be decreased when used in combination with Ibuprofen.Approved, Investigational
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Ibuprofen.Approved
NifenazoneThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Niflumic Acid.Approved
NiguldipineThe therapeutic efficacy of Niguldipine can be decreased when used in combination with Ibuprofen.Experimental
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Ibuprofen.Approved, Investigational
NilvadipineThe therapeutic efficacy of Nilvadipine can be decreased when used in combination with Ibuprofen.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe therapeutic efficacy of Nimodipine can be decreased when used in combination with Ibuprofen.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Ibuprofen.Approved
NisoldipineThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Ibuprofen.Approved
NitrendipineThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Ibuprofen.Approved, Investigational
NitroaspirinThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Nitroaspirin.Investigational
NitroprussideThe therapeutic efficacy of Nitroprusside can be decreased when used in combination with Ibuprofen.Approved, Investigational
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Ibuprofen.Approved
NorfloxacinIbuprofen may increase the neuroexcitatory activities of Norfloxacin.Approved
NS-398The risk or severity of adverse effects can be increased when Ibuprofen is combined with NS-398.Experimental
OctreotideThe serum concentration of Octreotide can be increased when it is combined with Ibuprofen.Approved, Investigational
OdanacatibThe serum concentration of Odanacatib can be increased when it is combined with Ibuprofen.Investigational
OfloxacinIbuprofen may increase the neuroexcitatory activities of Ofloxacin.Approved
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Ibuprofen.Approved, Investigational
OlmesartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olmesartan is combined with Ibuprofen.Approved, Investigational
OlsalazineThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Ibuprofen is combined with Omacetaxine mepesuccinate.Approved, Investigational
OmapatrilatThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuprofen is combined with Omapatrilat.Investigational
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Ibuprofen.Approved, Investigational
OmeprazoleThe serum concentration of Omeprazole can be increased when it is combined with Ibuprofen.Approved, Investigational, Vet Approved
OndansetronThe serum concentration of Ondansetron can be increased when it is combined with Ibuprofen.Approved
OrbifloxacinIbuprofen may increase the neuroexcitatory activities of Orbifloxacin.Vet Approved
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Ibuprofen.Approved
OtamixabanThe risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Ibuprofen.Approved
OxcarbazepineThe serum concentration of Ibuprofen can be decreased when it is combined with Oxcarbazepine.Approved
Oxolinic acidIbuprofen may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololIbuprofen may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Oxyphenbutazone.Approved, Withdrawn
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Ibuprofen.Approved, Vet Approved
PaliperidoneThe serum concentration of Paliperidone can be increased when it is combined with Ibuprofen.Approved
PamidronateThe risk or severity of gastrointestinal bleeding can be increased when Ibuprofen is combined with Pamidronate.Approved
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Ibuprofen.Approved, Investigational
PantoprazoleThe serum concentration of Pantoprazole can be increased when it is combined with Ibuprofen.Approved
ParamethasoneThe risk or severity of gastrointestinal irritation can be increased when Paramethasone is combined with Ibuprofen.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Parecoxib.Approved
PargylineThe therapeutic efficacy of Pargyline can be decreased when used in combination with Ibuprofen.Approved
ParitaprevirThe serum concentration of Paritaprevir can be increased when it is combined with Ibuprofen.Approved, Investigational
ParnaparinThe risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with Parnaparin.Approved, Investigational
ParomomycinThe risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Paromomycin.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Ibuprofen.Approved
PazufloxacinIbuprofen may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinIbuprofen may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololIbuprofen may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
PentamidineThe risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Pentamidine.Approved, Investigational
PentazocineThe serum concentration of Pentazocine can be increased when it is combined with Ibuprofen.Approved, Vet Approved
PentoliniumThe therapeutic efficacy of Pentolinium can be decreased when used in combination with Ibuprofen.Approved
Pentosan PolysulfateThe risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuprofen is combined with Perindopril.Approved
PerindoprilatThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuprofen is combined with Perindoprilat.Experimental
PhenindioneThe risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with Phenindione.Approved, Investigational
PhenobarbitalThe serum concentration of Ibuprofen can be decreased when it is combined with Phenobarbital.Approved, Investigational
PhenothiazineThe serum concentration of Phenothiazine can be increased when it is combined with Ibuprofen.Vet Approved
PhenoxybenzamineThe therapeutic efficacy of Phenoxybenzamine can be decreased when used in combination with Ibuprofen.Approved
PhenprocoumonThe risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with Phenprocoumon.Approved, Investigational
PhentolamineThe therapeutic efficacy of Phentolamine can be decreased when used in combination with Ibuprofen.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Ibuprofen.Approved, Vet Approved
PhenytoinThe serum concentration of Ibuprofen can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PibrentasvirThe serum concentration of Pibrentasvir can be increased when it is combined with Ibuprofen.Approved, Investigational
PinacidilThe therapeutic efficacy of Pinacidil can be decreased when used in combination with Ibuprofen.Approved
PindololIbuprofen may decrease the antihypertensive activities of Pindolol.Approved, Investigational
Pipemidic acidIbuprofen may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PiperineThe metabolism of Ibuprofen can be decreased when combined with Piperine.Investigational
PiretanideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Ibuprofen.Approved
Piromidic acidIbuprofen may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Ibuprofen.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Pirprofen.Experimental
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Ibuprofen.Approved
PitolisantThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Pitolisant.Approved, Investigational
PlazomicinThe risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Plazomicin.Approved, Investigational
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Ibuprofen.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Ibuprofen.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Ibuprofen.Approved, Investigational
Potassium CitrateThe risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with Potassium Citrate.Approved, Investigational, Vet Approved
PractololIbuprofen may decrease the antihypertensive activities of Practolol.Approved
PralatrexateIbuprofen may decrease the excretion rate of Pralatrexate which could result in a higher serum level.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Pranoprofen.Experimental, Investigational
PrasugrelThe risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with Prasugrel.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Ibuprofen.Approved
PrazosinThe therapeutic efficacy of Prazosin can be decreased when used in combination with Ibuprofen.Approved
PrednicarbateThe risk or severity of gastrointestinal irritation can be increased when Prednicarbate is combined with Ibuprofen.Approved, Investigational
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Ibuprofen.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Ibuprofen.Approved, Vet Approved
PrednylideneThe risk or severity of gastrointestinal irritation can be increased when Prednylidene is combined with Ibuprofen.Experimental
PrimidoneThe serum concentration of Ibuprofen can be decreased when it is combined with Primidone.Approved, Vet Approved
ProbenecidProbenecid may decrease the excretion rate of Ibuprofen which could result in a higher serum level.Approved, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Propacetamol.Approved, Investigational
PropafenoneIbuprofen may decrease the antihypertensive activities of Propafenone.Approved
PropranololIbuprofen may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Proquazone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Ibuprofen.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Ibuprofen.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Ibuprofen.Vet Approved
Protein CThe risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with Protein C.Approved
Protein S humanThe risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with Protein S human.Approved
ProtocatechualdehydeThe risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with Protocatechualdehyde.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Ibuprofen.Approved
PrulifloxacinIbuprofen may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PuromycinThe risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Puromycin.Experimental
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Ibuprofen.Approved
QuinaprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuprofen is combined with Quinapril.Approved, Investigational
QuinaprilatThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuprofen is combined with Quinaprilat.Experimental
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Ibuprofen.Approved
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Ibuprofen.Approved, Investigational
RamiprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuprofen is combined with Ramipril.Approved
RamiprilatThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuprofen is combined with Ramiprilat.Experimental
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Ibuprofen.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Ibuprofen.Approved, Investigational
RegorafenibThe serum concentration of Regorafenib can be increased when it is combined with Ibuprofen.Approved
RemikirenThe therapeutic efficacy of Remikiren can be decreased when used in combination with Ibuprofen.Approved
RescinnamineThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuprofen is combined with Rescinnamine.Approved
ReserpineThe therapeutic efficacy of Reserpine can be decreased when used in combination with Ibuprofen.Approved, Investigational
ReteplaseThe risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with Reteplase.Approved, Investigational
ReviparinThe risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with Reviparin.Approved, Investigational
Rhodamine 6GThe serum concentration of Rhodamine 6G can be increased when it is combined with Ibuprofen.Experimental
RibostamycinThe risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Ribostamycin.Approved, Investigational
RifampicinThe serum concentration of Ibuprofen can be decreased when it is combined with Rifampicin.Approved
RifamycinThe metabolism of Ibuprofen can be increased when combined with Rifamycin.Investigational
RifapentineThe metabolism of Ibuprofen can be increased when combined with Rifapentine.Approved, Investigational
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Ibuprofen.Approved, Investigational
RilmenidineThe therapeutic efficacy of Rilmenidine can be decreased when used in combination with Ibuprofen.Approved, Investigational
RimexoloneThe risk or severity of gastrointestinal irritation can be increased when Rimexolone is combined with Ibuprofen.Approved
RiociguatThe therapeutic efficacy of Riociguat can be decreased when used in combination with Ibuprofen.Approved
RisedronateThe risk or severity of gastrointestinal bleeding can be increased when Ibuprofen is combined with Risedronate.Approved, Investigational
RitonavirThe serum concentration of Ibuprofen can be decreased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Ibuprofen.Approved
RobenacoxibThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Robenacoxib.Experimental, Vet Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Ibuprofen.Approved, Investigational, Withdrawn
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Ibuprofen.Approved, Investigational
RosoxacinIbuprofen may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RucaparibThe serum concentration of Rucaparib can be increased when it is combined with Ibuprofen.Approved, Investigational
RufloxacinIbuprofen may increase the neuroexcitatory activities of Rufloxacin.Experimental
SalicylamideThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Ibuprofen.Approved, Investigational, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Salsalate.Approved
SaprisartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Saprisartan is combined with Ibuprofen.Experimental
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Ibuprofen.Approved, Investigational
SarafloxacinIbuprofen may increase the neuroexcitatory activities of Sarafloxacin.Vet Approved, Withdrawn
SaralasinThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Saralasin is combined with Ibuprofen.Investigational
SaruplaseThe risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with Saruplase.Experimental
SC-236The risk or severity of adverse effects can be increased when Ibuprofen is combined with SC-236.Experimental, Investigational
SecobarbitalThe metabolism of Ibuprofen can be increased when combined with Secobarbital.Approved, Vet Approved
SelexipagThe therapeutic efficacy of Selexipag can be decreased when used in combination with Ibuprofen.Approved
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Ibuprofen.Approved
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Ibuprofen.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Ibuprofen.Approved
SirolimusThe serum concentration of Sirolimus can be increased when it is combined with Ibuprofen.Approved, Investigational
SisomicinThe risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Sisomicin.Investigational
SitafloxacinIbuprofen may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Ibuprofen.Approved, Investigational
SitaxentanThe therapeutic efficacy of Sitaxentan can be decreased when used in combination with Ibuprofen.Approved, Investigational, Withdrawn
Sodium CitrateThe risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with Sodium Citrate.Approved, Investigational
Sodium phosphate, monobasicThe risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Ibuprofen.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Ibuprofen.Approved
SomatostatinThe serum concentration of Somatostatin can be increased when it is combined with Ibuprofen.Approved, Investigational
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Ibuprofen.Approved, Investigational
SotalolIbuprofen may decrease the antihypertensive activities of Sotalol.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Ibuprofen.Approved, Investigational
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Ibuprofen.Experimental
SpiraprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuprofen is combined with Spirapril.Approved
SpironolactoneThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuprofen is combined with Spironolactone.Approved
StanoloneThe serum concentration of Stanolone can be increased when it is combined with Ibuprofen.Illicit, Investigational
Stanolone acetateThe serum concentration of Stanolone acetate can be increased when it is combined with Ibuprofen.Experimental
StreptokinaseThe risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with Streptokinase.Approved, Investigational
StreptomycinThe risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Streptomycin.Approved, Vet Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Ibuprofen.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Ibuprofen.Approved, Investigational
SulodexideThe risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Ibuprofen.Investigational
SumatriptanThe serum concentration of Sumatriptan can be increased when it is combined with Ibuprofen.Approved, Investigational
SunitinibThe serum concentration of Sunitinib can be increased when it is combined with Ibuprofen.Approved, Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Ibuprofen.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Suxibuzone.Experimental
TacrineThe serum concentration of Tacrine can be increased when it is combined with Ibuprofen.Investigational, Withdrawn
TacrolimusThe risk or severity of renal failure can be increased when Ibuprofen is combined with Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Ibuprofen.Approved
TalinololIbuprofen may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Talniflumate.Approved
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Ibuprofen.Approved
TasosartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Ibuprofen.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Ibuprofen.Experimental
Technetium Tc-99m ciprofloxacinIbuprofen may increase the neuroexcitatory activities of Technetium Tc-99m ciprofloxacin.Investigational
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Ibuprofen.Approved, Investigational
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Ibuprofen.Approved, Withdrawn
TelmisartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Ibuprofen.Approved, Investigational
TemafloxacinIbuprofen may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuprofen is combined with Temocapril.Experimental, Investigational
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Ibuprofen.Approved
TenecteplaseThe risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with Tenecteplase.Approved
TenidapThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Tenidap.Experimental
TeniposideThe serum concentration of Teniposide can be increased when it is combined with Ibuprofen.Approved
TenofovirThe serum concentration of Tenofovir can be increased when it is combined with Ibuprofen.Experimental, Investigational
Tenofovir alafenamideThe serum concentration of Tenofovir alafenamide can be increased when it is combined with Ibuprofen.Approved
Tenofovir disoproxilIbuprofen may decrease the excretion rate of Tenofovir disoproxil which could result in a higher serum level.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Ibuprofen.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Tepoxalin.Vet Approved
TerazosinThe therapeutic efficacy of Terazosin can be decreased when used in combination with Ibuprofen.Approved
TerfenadineThe serum concentration of Terfenadine can be increased when it is combined with Ibuprofen.Approved, Withdrawn
TertatololIbuprofen may decrease the antihypertensive activities of Tertatolol.Experimental
Testosterone propionateThe serum concentration of Ibuprofen can be decreased when it is combined with Testosterone propionate.Approved, Investigational, Vet Approved, Withdrawn
TetracyclineThe serum concentration of Tetracycline can be increased when it is combined with Ibuprofen.Approved, Vet Approved
TetrahydropalmatineThe therapeutic efficacy of Tetrahydropalmatine can be decreased when used in combination with Ibuprofen.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Tiaprofenic acid.Approved
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Ibuprofen.Approved
TicrynafenThe therapeutic efficacy of Ticrynafen can be decreased when used in combination with Ibuprofen.Withdrawn
Tiludronic acidThe risk or severity of gastrointestinal bleeding can be increased when Ibuprofen is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololIbuprofen may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Tinoridine.Investigational
TinzaparinThe risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with Tinzaparin.Approved
TioclomarolThe risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with Tioclomarol.Experimental
TipranavirThe serum concentration of Ibuprofen can be decreased when it is combined with Tipranavir.Approved, Investigational
TixocortolThe risk or severity of gastrointestinal irritation can be increased when Tixocortol is combined with Ibuprofen.Approved, Withdrawn
TobramycinThe risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Tobramycin.Approved, Investigational
TocopherylquinoneThe therapeutic efficacy of Tocopherylquinone can be decreased when used in combination with Ibuprofen.Experimental, Investigational
TolazamideThe protein binding of Tolazamide can be decreased when combined with Ibuprofen.Approved, Investigational
TolazolineThe therapeutic efficacy of Tolazoline can be decreased when used in combination with Ibuprofen.Approved, Vet Approved
TolbutamideThe protein binding of Tolbutamide can be decreased when combined with Ibuprofen.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Tolfenamic Acid.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Ibuprofen.Approved
TolonidineThe therapeutic efficacy of Tolonidine can be decreased when used in combination with Ibuprofen.Experimental
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Ibuprofen.Approved
TopiramateThe serum concentration of Topiramate can be increased when it is combined with Ibuprofen.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Ibuprofen.Approved, Investigational
TorasemideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Ibuprofen.Approved
TrandolaprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuprofen is combined with Trandolapril.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Ibuprofen.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Ibuprofen.Approved
TreprostinilThe risk or severity of bleeding can be increased when Treprostinil is combined with Ibuprofen.Approved, Investigational
TriamcinoloneThe risk or severity of gastrointestinal irritation can be increased when Triamcinolone is combined with Ibuprofen.Approved, Vet Approved
TriamtereneThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuprofen is combined with Triamterene.Approved
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Ibuprofen.Approved, Vet Approved
TrifluoperazineThe serum concentration of Trifluoperazine can be increased when it is combined with Ibuprofen.Approved, Investigational
TriflusalThe risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with Triflusal.Approved, Investigational
TrilostaneThe risk or severity of gastrointestinal irritation can be increased when Trilostane is combined with Ibuprofen.Approved, Investigational, Vet Approved, Withdrawn
TrimazosinThe therapeutic efficacy of Trimazosin can be decreased when used in combination with Ibuprofen.Experimental
TrimethaphanThe therapeutic efficacy of Trimethaphan can be decreased when used in combination with Ibuprofen.Approved, Investigational
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Ibuprofen.Approved
Trolamine salicylateThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Trolamine salicylate.Approved
TrovafloxacinIbuprofen may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinThe risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with Troxerutin.Investigational
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Ibuprofen.Approved, Investigational, Nutraceutical
UlobetasolThe risk or severity of gastrointestinal irritation can be increased when Ulobetasol is combined with Ibuprofen.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Ibuprofen.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Ibuprofen.Approved, Investigational
UrapidilThe therapeutic efficacy of Urapidil can be decreased when used in combination with Ibuprofen.Investigational
UrokinaseThe risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with Urokinase.Approved, Investigational, Withdrawn
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Ibuprofen.Approved, Investigational, Withdrawn
ValinomycinThe serum concentration of Valinomycin can be increased when it is combined with Ibuprofen.Experimental
Valproic AcidThe metabolism of Ibuprofen can be decreased when combined with Valproic Acid.Approved, Investigational
ValsartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Valsartan is combined with Ibuprofen.Approved, Investigational
ValspodarThe serum concentration of Valspodar can be increased when it is combined with Ibuprofen.Investigational
VancomycinIbuprofen may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Ibuprofen.Approved
VelpatasvirThe serum concentration of Velpatasvir can be increased when it is combined with Ibuprofen.Approved, Investigational
VemurafenibThe serum concentration of Vemurafenib can be increased when it is combined with Ibuprofen.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Ibuprofen.Approved, Investigational
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Ibuprofen.Approved
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Ibuprofen.Approved
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Ibuprofen.Approved
VincamineThe therapeutic efficacy of Vincamine can be decreased when used in combination with Ibuprofen.Experimental
VincristineThe excretion of Vincristine can be decreased when combined with Ibuprofen.Approved, Investigational
VinflunineThe serum concentration of Vinflunine can be increased when it is combined with Ibuprofen.Approved, Investigational
VinorelbineThe serum concentration of Vinorelbine can be increased when it is combined with Ibuprofen.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Ibuprofen.Approved, Investigational
VorapaxarThe risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with Vorapaxar.Approved
VoriconazoleThe serum concentration of Ibuprofen can be increased when it is combined with Voriconazole.Approved, Investigational
VoxilaprevirThe serum concentration of Voxilaprevir can be increased when it is combined with Ibuprofen.Approved, Investigational
WarfarinThe risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with Warfarin.Approved
XimelagatranThe risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with Ximelagatran.Approved, Investigational, Withdrawn
XipamideThe therapeutic efficacy of Xipamide can be decreased when used in combination with Ibuprofen.Experimental
ZaltoprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Zaltoprofen.Approved, Investigational
ZidovudineThe serum concentration of Ibuprofen can be decreased when it is combined with Zidovudine.Approved
ZofenoprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuprofen is combined with Zofenopril.Experimental
Zoledronic acidThe risk or severity of gastrointestinal bleeding can be increased when Ibuprofen is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Zomepirac.Withdrawn
Food Interactions
  • Avoid alcohol
  • Food delays the time to reach peak plasma concentrations by 30-60 minutes and reduces peak plasma concentrations by 30-50%. Extent of absorption is unaffected.
  • Take with food to reduce gastric irritation.

References

Synthesis Reference

http://en.wikipedia.org/wiki/Ibuprofen#Synthesis

General References
  1. Zawada ET Jr: Renal consequences of nonsteroidal antiinflammatory drugs. Postgrad Med. 1982 May;71(5):223-30. [PubMed:7041104]
  2. Townsend KP, Pratico D: Novel therapeutic opportunities for Alzheimer's disease: focus on nonsteroidal anti-inflammatory drugs. FASEB J. 2005 Oct;19(12):1592-601. [PubMed:16195368]
  3. Chen H, Jacobs E, Schwarzschild MA, McCullough ML, Calle EE, Thun MJ, Ascherio A: Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease. Ann Neurol. 2005 Dec;58(6):963-7. [PubMed:16240369]
  4. Geisslinger G, Dietzel K, Bezler H, Nuernberg B, Brune K: Therapeutically relevant differences in the pharmacokinetical and pharmaceutical behavior of ibuprofen lysinate as compared to ibuprofen acid. Int J Clin Pharmacol Ther Toxicol. 1989 Jul;27(7):324-8. [PubMed:2777420]
  5. Bergner T, Przybilla B: Photosensitization caused by ibuprofen. J Am Acad Dermatol. 1992 Jan;26(1):114-6. [PubMed:1531054]
  6. Dill J, Patel AR, Yang XL, Bachoo R, Powell CM, Li S: A molecular mechanism for ibuprofen-mediated RhoA inhibition in neurons. J Neurosci. 2010 Jan 20;30(3):963-72. doi: 10.1523/JNEUROSCI.5045-09.2010. [PubMed:20089905]
External Links
Human Metabolome Database
HMDB0001925
KEGG Drug
D00126
KEGG Compound
C01588
PubChem Compound
3672
PubChem Substance
46507255
ChemSpider
3544
BindingDB
50009859
ChEBI
5855
ChEMBL
CHEMBL521
Therapeutic Targets Database
DAP000780
PharmGKB
PA449957
IUPHAR
2713
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Ibuprofen
ATC Codes
M02AA13 — IbuprofenR02AX02 — IbuprofenC01EB16 — IbuprofenM01AE51 — Ibuprofen, combinationsM01AE01 — IbuprofenG02CC01 — Ibuprofen
AHFS Codes
  • 28:08.04.92 — Other Nonsteroidal Antiimflammatory Agents
FDA label
Download (1.77 MB)
MSDS
Download (73.5 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedTreatmentFracture, Ankle1
0CompletedTreatmentPrimary Dysmenorrhoea1
0Not Yet RecruitingTreatmentPostoperative pain1
1CompletedNot AvailableAutonomic Failure / Idiopathic orthostatic hypotension1
1CompletedNot AvailableBioequivalence1
1CompletedNot AvailableHealthy Volunteers8
1CompletedBasic ScienceBioequivalence of the Test Formulation1
1CompletedBasic ScienceHealthy Volunteer Study2
1CompletedBasic ScienceHealthy Volunteers5
1CompletedBasic ScienceHealthy Volunteers / Inflammatory Reaction / Pain1
1CompletedBasic ScienceInflammatory Reaction / Pain1
1CompletedBasic SciencePain4
1CompletedBasic SciencePharmacokinetics1
1CompletedDiagnosticBone destruction / Osteoarthritis (OA)1
1CompletedOtherModerate Pain1
1CompletedPreventionGastroduodenal Erosions1
1CompletedPreventionOther and unspecified effects of high altitude1
1CompletedSupportive CareBalanitis / Paraphimosis / Phimosis / Postoperative pain1
1CompletedTreatmentAllergic Rhinitis (AR)1
1CompletedTreatmentBioequivalency2
1CompletedTreatmentHealthy Volunteers11
1CompletedTreatmentKnee Osteoarthritis (Knee OA)1
1CompletedTreatmentNSAID Related Gastric Irritation1
1CompletedTreatmentOsteoarthritis (OA)1
1CompletedTreatmentPain1
1CompletedTreatmentSpinal Cord Injuries (SCI)1
1Not Yet RecruitingTreatmentTonsillectomy With or Without Adenoidectomy1
1RecruitingTreatmentNeonates / Patent Ductus Arteriosus (PDA)1
1TerminatedTreatmentHealthy Volunteers1
1Unknown StatusBasic ScienceKnee Osteoarthritis (Knee OA)1
1Unknown StatusBasic ScienceOther and unspecified effects of high altitude1
1Unknown StatusTreatmentAlzheimer's Disease (AD)1
1Unknown StatusTreatmentDuchenne's Muscular Dystrophy (DMD)1
1, 2CompletedTreatmentTemporomandibular Joint Disorders1
1, 2Enrolling by InvitationPreventionAnalgesic Drugs / Pain Relief1
1, 2Not Yet RecruitingTreatmentAdenotonsillectomy / Opioids Use / Post-operative Analgesia1
1, 2Unknown StatusTreatmentChoroidal Melanoma / Eye Neoplasms / Melanoma1
1, 2Unknown StatusTreatmentInfant, Extremely Premature / IV Ibuprofen / Oral Ibuprofen / Patent Ductus Arteriosus (PDA)1
2Active Not RecruitingPreventionRetinopathy of Prematurity1
2Active Not RecruitingTreatmentBronchopulmonary Dysplasia (BPD)1
2Active Not RecruitingTreatmentImpacted Wisdom Teeth1
2Active Not RecruitingTreatmentTuberculosis1
2CompletedBasic ScienceSkeletal Muscle Mass Regulation1
2CompletedOtherComplication Due to Immunization1
2CompletedSupportive CareStomatitis, Aphthous1
2CompletedTreatmentAcute Sore Throat Pain1
2CompletedTreatmentAdenoidectomy / Tonsillectomy1
2CompletedTreatmentCervical Strain1
2CompletedTreatmentContraception1
2CompletedTreatmentDelayed Onset Muscle Soreness1
2CompletedTreatmentDelayed Onset Muscle Soreness, DOMS1
2CompletedTreatmentDental Pain1
2CompletedTreatmentDiabetes, Diabetes Mellitus Type 11
2CompletedTreatmentDysmenorrhea1
2CompletedTreatmentIrreversible Pulpitis / Pain / Postoperative pain1
2CompletedTreatmentMigraines1
2CompletedTreatmentOsteoarthritis (OA)1
2CompletedTreatmentPain6
2CompletedTreatmentPain, Acute1
2CompletedTreatmentPost-Operative Pain1
2CompletedTreatmentPostoperative Dental Pain1
2CompletedTreatmentPostoperative pain1
2CompletedTreatmentSoft Tissue Injury1
2Enrolling by InvitationSupportive CareGingivostomatitis / Hand, Foot, and Mouth Disease / Herpangina1
2Not Yet RecruitingSupportive CareCarpal Tunnel Syndrome (CTS) / Cystic tumour of the ganglia / De Quervain's Disease / Dupuytren's Contracture / Trigger Digit1
2Not Yet RecruitingTreatmentConcussion, Brain1
2Not Yet RecruitingTreatmentGeneral Surgery1
2RecruitingBasic ScienceChronic Granulomatous Disease X-linked (X-CGD)1
2RecruitingPreventionFertilization in Vitro/Methods / Ovulation / Ovulation Inhibition / Ovulation Inhibition/Drug Effects / Pregnancy1
2RecruitingPreventionPost-ERCP Acute Pancreatitis1
2RecruitingSupportive CareCognitive Impairments / Stage 0 Colorectal Cancer / Stage I Colorectal Cancer / Stage II Colorectal Cancer / Stage IIA Colorectal Cancer / Stage IIB Colorectal Cancer / Stage IIC Colorectal Cancer / Stage III Colorectal Cancer / Stage IIIA Colorectal Cancer / Stage IIIB Colorectal Cancer / Stage IIIC Colorectal Cancer1
2RecruitingTreatmentCancer-related Cognitive Difficulties1
2RecruitingTreatmentCervical Spondylosis / Lumbar Spondylosis1
2RecruitingTreatmentComatose / Hyperpyrexia / Parasitemia / Plasmodium Infections / Seizures1
2RecruitingTreatmentPain Management1
2RecruitingTreatmentPatent Ductus Arteriosus (PDA)1
2RecruitingTreatmentSunburn1
2RecruitingTreatmentPainful musculoskeletal conditions1
2TerminatedTreatmentPost-surgical Dental Pain1
2TerminatedTreatmentPostsurgical Pain Due to Third Molar Extraction1
2Unknown StatusPreventionPost Bronchoscopy Fever1
2Unknown StatusPreventionSpectrum of Altitude-associated Neurologic Forms of Altitude1
2Unknown StatusSupportive CareMetastatic Cancers1
2Unknown StatusTreatmentImpacted Third Molar Tooth1
2WithdrawnTreatmentDental Pain1
2WithdrawnTreatmentHb-SS Disease With Vasoocclusive Pain / Hemoglobin SS Disease With Crisis / Hemoglobin SS Disease With Vasoocclusive Crisis / Other Sickle Cell Disease With Vaso-Occlusive Pain / Sickle Cell Disorders1
2WithdrawnTreatmentPatent Ductus Arteriosus (PDA)1
2, 3CompletedBasic ScienceMajor Depressive Disorder (MDD)1
2, 3CompletedSupportive CareHigh Blood Pressure (Hypertension)1
2, 3CompletedTreatmentCervicobrachial Neuralgia1
2, 3CompletedTreatmentIdiopathic Intracranial Hypertension (IIH)1
2, 3CompletedTreatmentLow Back Pain (LBP)1
2, 3CompletedTreatmentPatent Ductus Arteriosus (PDA)1
2, 3RecruitingTreatmentChronic Rhinosinusitis (Diagnosis)1
2, 3RecruitingTreatmentHemodynamically Significant Patent Ductus Arteriosus in Preterm Infants / Patent Ductus Arteriosus (PDA)1
2, 3RecruitingTreatmentPatent Ductus Arteriosus (PDA) / Respiratory Distress Syndrome (RDS)1
3Active Not RecruitingTreatmentAcute Ankle Sprain1
3Active Not RecruitingTreatmentCerebral Palsy (CP)1
3Active Not RecruitingTreatmentPatent Ductus Arteriosus (PDA)1
3CompletedNot AvailablePain1
3CompletedPreventionAcute Kidney Injury (AKI) / Exercise-associated Hyponatremia / Perceived Exertion1
3CompletedPreventionAltitude Sickness1
3CompletedPreventionChronic Low Back Pain (CLBP) / Chronic Regional Pain Syndrome / Chronic Soft Tissue Pain / Osteoarthritis (OA) / Rheumatoid Arthritis1
3CompletedPreventionIUD Removal1
3CompletedPreventionPeptic Ulcers1
3CompletedPreventionUlcers1
3CompletedTreatmentAcute Respiratory Distress Syndrome (ARDS) / Chronic Lung Diseases / Shock, Septic1
3CompletedTreatmentAcute Sore Throat Pain1
3CompletedTreatmentAsthma Bronchial / Wheezing1
3CompletedTreatmentBack Pain / Cervical Pain1
3CompletedTreatmentDelayed Onset Muscle Soreness, DOMS1
3CompletedTreatmentDental Pain1
3CompletedTreatmentDysmenorrhea1
3CompletedTreatmentFevers4
3CompletedTreatmentFevers / Respiratory Tract Infections (RTI)1
3CompletedTreatmentForearm Fractures1
3CompletedTreatmentLow Back Pain (LBP)1
3CompletedTreatmentModerate or Severe Submental Fullness1
3CompletedTreatmentOsteoarthritis (OA)1
3CompletedTreatmentPain9
3CompletedTreatmentPain / Post-Operative Pain / Third Molar Extraction1
3CompletedTreatmentPain / Pregnancy1
3CompletedTreatmentPatent Ductus Arteriosus (PDA)2
3CompletedTreatmentPost Operative Dental Pain1
3CompletedTreatmentPost-Operative Pain1
3CompletedTreatmentPost-surgical Pain Following Extraction of Molar Teeth1
3CompletedTreatmentPostoperative Dental Pain1
3CompletedTreatmentPostoperative pain1
3CompletedTreatmentPostoperative pain / Tooth Diseases1
3CompletedTreatmentPrimary Dysmenorrhoea1
3CompletedTreatmentTonsillectomy1
3CompletedTreatmentMinor burns1
3Not Yet RecruitingTreatmentCold1
3Not Yet RecruitingTreatmentHernia / Pain1
3Not Yet RecruitingTreatmentLow Back Pain (LBP)1
3RecruitingSupportive CareMalignant Head and Neck Neoplasm / Mucositis / Radiation-Induced Disorder1
3RecruitingTreatmentAcute Musculoskeletal Disease / Emergency / Pain, Acute / Sprains / Sprains and Strains / Traumas / Traumatic Injuries1
3RecruitingTreatmentAlzheimer's Disease (AD)1
3RecruitingTreatmentLong-bone Fractures / Pain1
3RecruitingTreatmentPatent Ductus Arteriosus (PDA)1
3RecruitingTreatmentPost Operative Pain1
3RecruitingTreatmentPostoperative pain / Surgery, Outpatient1
3TerminatedTreatmentDysmenorrhea1
3TerminatedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
3TerminatedTreatmentInfection NOS1
3TerminatedTreatmentModerate to Severe Primary Dysmenorrhea1
3TerminatedTreatmentPostoperative pain1
3Unknown StatusSupportive CarePostoperative pain1
3Unknown StatusTreatmentHeadaches1
3Unknown StatusTreatmentMuscular Atrophy / Sprains / Tendonitis1
3Unknown StatusTreatmentNeoplasms, Breast1
3Unknown StatusTreatmentPediatric Obstructive Sleep Apnea Syndrome1
3WithdrawnTreatmentOsteoarthritis (OA)1
3WithdrawnTreatmentPain1
3WithdrawnTreatmentAcute Rhinitis1
4Active Not RecruitingPreventionPain, Acute / Postoperative pain1
4Active Not RecruitingTreatmentEclampsia / HELLP Syndrome / Prophylaxis of preeclampsia1
4Active Not RecruitingTreatmentPatent Ductus Arteriosus (PDA)1
4CompletedNot AvailablePatent Ductus Arteriosus (PDA) / Prematurity of Fetus1
4CompletedBasic ScienceHealthy Volunteers2
4CompletedBasic ScienceIschaemic Heart Diseases / Osteoarthritis (OA)1
4CompletedBasic SciencePain1
4CompletedHealth Services ResearchPain1
4CompletedPreventionAcute Mountain Sickness, Blood Oxygen Saturation, Headache1
4CompletedPreventionArthroplasty, Replacement, Hip / Osteoarthritis, Hip / Rheumatoid Arthritis1
4CompletedPreventionOsteoarthritis (OA) / Rheumatoid Arthritis1
4CompletedPreventionPain Measurement1
4CompletedPreventionRecurrence of Febrile Seizure1
4CompletedPreventionStreptococcal Infections1
4CompletedPreventionVaccines, Pneumococcal1
4CompletedSupportive CareCongenital Muscular Torticollis1
4CompletedSupportive CareOrthodontic Pain1
4CompletedSupportive CarePain1
4CompletedSupportive CarePain / Pituitary Neoplasms1
4CompletedSupportive CareSymptomatic Uterine Fibroids and Adenomyosis1
4CompletedTreatmentAcute Cystitis (Excl in Pregnancy)1
4CompletedTreatmentAlzheimer's Disease (AD)1
4CompletedTreatmentAnalgesia / Postoperative pain1
4CompletedTreatmentAnalgesics1
4CompletedTreatmentArthroscopic Knee Surgery1
4CompletedTreatmentBMI >30 kg/m21
4CompletedTreatmentBariatric Surgery Candidate / Obesity, Morbid1
4CompletedTreatmentBreast Pain1
4CompletedTreatmentChronic Low Back Pain (CLBP)1
4CompletedTreatmentDental Pain1
4CompletedTreatmentFeeling Anxious / Nausea / Pain1
4CompletedTreatmentFevers3
4CompletedTreatmentFevers / Pain1
4CompletedTreatmentFracture Bone1
4CompletedTreatmentGallbladder disorders1
4CompletedTreatmentGastrointestinal Mucosal Damage1
4CompletedTreatmentGeneral Surgery1
4CompletedTreatmentHeadache, Tension-Type / Headaches / Tension-Type Headache (Episodic)1
4CompletedTreatmentHeat / Pain1
4CompletedTreatmentHigh Blood Pressure (Hypertension)1
4CompletedTreatmentHypertension, Pregnancy-Induced / Prophylaxis of preeclampsia1
4CompletedTreatmentImpaired Renal Function / Myocardial Infarction / Postoperative pain1
4CompletedTreatmentInfants, Premature / Patent Ductus Arteriosus (PDA)1
4CompletedTreatmentIrreversible Pulpitis1
4CompletedTreatmentJuvenile Idiopathic Arthritis (JIA)1
4CompletedTreatmentKnee Osteoarthritis (Knee OA)4
4CompletedTreatmentMigrainous Headache1
4CompletedTreatmentMosquito Bites1
4CompletedTreatmentMuscle Soreness1
4CompletedTreatmentNSAIDs / Pain Management1
4CompletedTreatmentNarcotic Use / Nausea / Occasional Constipation / Pain1
4CompletedTreatmentOpioids Use / Postoperative pain1
4CompletedTreatmentOsteoarthritis of the Hip or Knee1
4CompletedTreatmentPain8
4CompletedTreatmentPain, Acute1
4CompletedTreatmentPatent Ductus Arteriosus (PDA)2
4CompletedTreatmentPostoperative pain3
4CompletedTreatmentRelapsing Remitting Multiple Sclerosis (RRMS)1
4CompletedTreatmentRheumatoid Arthritis1
4CompletedTreatmentRotator Cuff Syndrome1
4CompletedTreatmentTraumas1
4CompletedTreatmentUrinary Tract Infections (UTIs)1
4Enrolling by InvitationTreatmentCarpal Tunnel / Cystic tumour of the ganglia / De Quervain's Disease / Trigger Finger1
4Not Yet RecruitingTreatmentAnalgesia / Percutaneous Nephrolithotomy1
4Not Yet RecruitingTreatmentAnalgesics, Opioid / Anti-Inflammatory Agents, Non-Steroidal / Child/Adolescent Problems / Emergency Service, Hospital / Fentanyl / Ibuprofen / Pain, Acute1
4Not Yet RecruitingTreatmentDistal Radius Fractures / Metacarpal Fractures / Pain Management1
4Not Yet RecruitingTreatmentLow Back Pain (LBP)1
4Not Yet RecruitingTreatmentPain1
4Not Yet RecruitingTreatmentPain, Acute1
4RecruitingPreventionAnaesthesia therapy / Hip Fractures1
4RecruitingSupportive CareCarpal Tunnel1
4RecruitingSupportive CareImpacted Third Molar Tooth / Other Surgical Procedures / Pain1
4RecruitingTreatmentAbortion Second Trimester1
4RecruitingTreatmentAcute Diverticulitis1
4RecruitingTreatmentCervical Preparation / Pain / Pregnancy Termination1
4RecruitingTreatmentEpisodic Migraine1
4RecruitingTreatmentFevers / Pain1
4RecruitingTreatmentFlu caused by Influenza1
4RecruitingTreatmentLow Back Pain (LBP)1
4RecruitingTreatmentLumbar Disc Disease / Lumbar Radiculopathy / Prolapsed Lumbar Disc1
4RecruitingTreatmentPain1
4RecruitingTreatmentPost-Cesarean Section / Postoperative pain1
4RecruitingTreatmentPostoperative pain2
4RecruitingTreatmentRib Fracture Multiple / Rib Fractures1
4RecruitingTreatmentRib Fractures / Wounds and Injuries1
4RecruitingTreatmentSciatica1
4SuspendedTreatmentRotator Cuff Syndrome1
4TerminatedPreventionHigh Blood Pressure (Hypertension)1
4TerminatedTreatmentAdverse Reaction to Drug / Obstructive Sleep Apnea (OSA) / Recurrent Tonsillitis / Sleep Disordered Breathing (SDB)1
4TerminatedTreatmentDepression / Depression, Myalgia1
4TerminatedTreatmentHematologic Diseases / Sickle Cell Disorders1
4TerminatedTreatmentInflammatory Responses1
4TerminatedTreatmentPain1
4TerminatedTreatmentPatent Ductus Arteriosus (PDA)1
4TerminatedTreatmentPeriodontitis1
4TerminatedTreatmentSickle Cell Disorders1
4Unknown StatusDiagnosticPatent Ductus Arteriosus (PDA)1
4Unknown StatusSupportive CareChronic Pelvic Pain1
4Unknown StatusTreatmentDental Extraction1
4Unknown StatusTreatmentFevers3
4Unknown StatusTreatmentPharyngitis1
4WithdrawnTreatmentArthritic Knee Pain1
4WithdrawnTreatmentPatent Ductus Arteriosus (PDA) / Very Low Birth Weight Infants1
Not AvailableActive Not RecruitingTreatmentColles Fracture1
Not AvailableActive Not RecruitingTreatmentPostoperative Pain Management1
Not AvailableCompletedNot AvailableAging / Physical Fitness1
Not AvailableCompletedNot AvailableConcussions / Headaches1
Not AvailableCompletedBasic ScienceAsthma, Allergic1
Not AvailableCompletedBasic ScienceBMI >30 kg/m21
Not AvailableCompletedBasic ScienceIschemic Reperfusion Injury1
Not AvailableCompletedBasic SciencePlatelet Aggregation1
Not AvailableCompletedBasic ScienceStability & Variability of Lipid-derived Molecules in Sweat1
Not AvailableCompletedDiagnosticDermatitis, Photocontact1
Not AvailableCompletedOtherAnti Inflammatory Non-Steroidal / Cystic Fibrosis (CF) / Neutrophils1
Not AvailableCompletedPreventionCardiovascular Disease (CVD)1
Not AvailableCompletedPreventionPostoperative pain / Wisdom Tooth1
Not AvailableCompletedPreventionBone destruction / Sarcopenia1
Not AvailableCompletedSupportive CareElbow Fractures1
Not AvailableCompletedSupportive CareHyperalgesia / Ibuprofen / Postoperative pain / Remifentanil1
Not AvailableCompletedSupportive CareInfertilities / Subfertility1
Not AvailableCompletedTreatmentAnalgesia Post Fracture / Upper Extremity Fractures1
Not AvailableCompletedTreatmentCancer, Breast1
Not AvailableCompletedTreatmentCystic Fibrosis (CF)2
Not AvailableCompletedTreatmentDiverticulitis1
Not AvailableCompletedTreatmentDysmenorrhea1
Not AvailableCompletedTreatmentFracture Bone1
Not AvailableCompletedTreatmentGlaucoma / Ocular Hypertension1
Not AvailableCompletedTreatmentHemophilia A / Human Immunodeficiency Virus (HIV) Infections1
Not AvailableCompletedTreatmentHernia, Abdominal / Inguinal Hernias / Laparoscopic Cholecystectomy / Umbilical Hernias1
Not AvailableCompletedTreatmentHypoxic Ischemic Encephalopathy (HIE) / Perinatal Asphyxia1
Not AvailableCompletedTreatmentKnee Osteoarthritis (Knee OA)4
Not AvailableCompletedTreatmentLow Back Pain (LBP)1
Not AvailableCompletedTreatmentMusculoskeletal Injuries1
Not AvailableCompletedTreatmentPain3
Not AvailableCompletedTreatmentPatent Ductus Arteriosus (PDA)3
Not AvailableCompletedTreatmentPneumonia1
Not AvailableCompletedTreatmentPostoperative pain1
Not AvailableCompletedTreatmentSkin Laxity1
Not AvailableCompletedTreatmentSpinal Stenosis of Lumbar Region1
Not AvailableCompletedTreatmentSpondyloarthritis, Axial1
Not AvailableCompletedTreatmentTemporomandibular Disorders1
Not AvailableEnrolling by InvitationOtherKnee Osteoarthritis (Knee OA)1
Not AvailableNot Yet RecruitingTreatmentInguinal Hernias1
Not AvailableRecruitingNot AvailableMultimodal Analgesia / Nonsteroidal Anti-inflammatory Drugs1
Not AvailableRecruitingOtherLocal Anesthesia1
Not AvailableRecruitingPreventionCachexia / Neoplasms1
Not AvailableRecruitingPreventionDisorder of Urinary Stent / Ureteral Spasm / Ureteropelvic Junction Obstruction / Urolithiasis1
Not AvailableRecruitingPreventionImmune System and Related Disorders1
Not AvailableRecruitingTreatmentBiliary Colic1
Not AvailableRecruitingTreatmentHigh Altitude Headache / Other and unspecified effects of high altitude1
Not AvailableRecruitingTreatmentHypertension, Pregnancy-Induced1
Not AvailableRecruitingTreatmentInguinal Surgery1
Not AvailableRecruitingTreatmentPatent Ductus Arteriosus (PDA)2
Not AvailableRecruitingTreatmentRotator Cuff Tear Arthropathy1
Not AvailableSuspendedTreatmentLaceration / Pain1
Not AvailableTerminatedPreventionPain1
Not AvailableTerminatedTreatmentCachexia / Cancer, Advanced1
Not AvailableTerminatedTreatmentPain, Chronic1
Not AvailableTerminatedTreatmentPatent Ductus Arteriosus (PDA) / Premature Babies1
Not AvailableTerminatedTreatmentPatent Ductus Arteriosus (PDA) / Preterm Infants1
Not AvailableTerminatedTreatmentSevere Traumatic Brain Injury / Subarachnoid Hemorrhage1
Not AvailableTerminatedTreatmentSoft Tissue Injury1
Not AvailableUnknown StatusNot AvailableFevers1
Not AvailableUnknown StatusBasic ScienceMalignant Neoplasm of Colon1
Not AvailableUnknown StatusPreventionOral Ibuprofen Prophylaxis in Very Low Birth Weight Infants1
Not AvailableUnknown StatusSupportive CarePrimary Post Tonsillectomy Hemorrhage / Secondary Post Tonsillectomy Hemorrhage1
Not AvailableUnknown StatusTreatmentFevers1
Not AvailableUnknown StatusTreatmentFlail Chest / General Surgery / Rib Fractures / Traumas1
Not AvailableUnknown StatusTreatmentFracture Bone / Pain1
Not AvailableUnknown StatusTreatmentPain1
Not AvailableUnknown StatusTreatmentPleuro-pneumonia1
Not AvailableWithdrawnSupportive CareToothache1
Not AvailableWithdrawnTreatmentPsychiatric Disorder NOS1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • Abbott Laboratories Ltd.
  • Actavis Group
  • Advanced Pharmaceutical Services Inc.
  • Aidarex Pharmacuticals LLC
  • Altura Pharmaceuticals Inc.
  • Amerisource Health Services Corp.
  • Amneal Pharmaceuticals
  • Apotheca Inc.
  • Apothecary Shop Wholesale
  • A-S Medication Solutions LLC
  • Ascend Laboratories LLC
  • Atlantic Biologicals Corporation
  • BASF Corp.
  • Bayer Healthcare
  • Ben Venue Laboratories Inc.
  • Blenheim Pharmacal
  • Breckenridge Pharmaceuticals
  • Bryant Ranch Prepack
  • Bv Pharbita
  • Cardinal Health
  • Caremark LLC
  • Central Texas Community Health Centers
  • Centrix Pharmaceuticals
  • Chain Drug
  • Corepharma LLC
  • Coupler Enterprises Inc.
  • Cumberland Pharmaceuticals
  • CVS Pharmacy
  • Darby Dental Supply Co. Inc.
  • Dept Health Central Pharmacy
  • DHHS Program Support Center Supply Service Center
  • Direct Dispensing Inc.
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Doctor Reddys Laboratories Ltd.
  • Dorx LLC
  • Eckerd
  • Equaline Vitamins
  • Gm Pharmaceuticals Inc.
  • Golden State Medical Supply Inc.
  • Greenstone LLC
  • Group Health Cooperative
  • H and H Laboratories
  • H.J. Harkins Co. Inc.
  • Hawthorn Pharmaceuticals
  • Heartland Repack Services LLC
  • Hl Moore Drug Exchange
  • Imiren Pharmaceuticals Inc.
  • Innoviant Pharmacy Inc.
  • Ivax Pharmaceuticals
  • Kaiser Foundation Hospital
  • Keltman Pharmaceuticals Inc.
  • Kowa Pharmaceuticals America Inc.
  • Lake Erie Medical and Surgical Supply
  • LeaderPharma
  • Legacy Pharmaceuticals Packaging LLC
  • Liberty Pharmaceuticals
  • Lundbeck Inc.
  • Major Pharmaceuticals
  • Mckesson Corp.
  • McNeil Laboratories
  • Medicine Shop
  • Medique Products
  • Medisca Inc.
  • Medvantx Inc.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Nucare Pharmaceuticals Inc.
  • Palmetto Pharmaceuticals Inc.
  • Par Pharmaceuticals
  • Particle Dynamics Co.
  • Patient First Corp.
  • PCA LLC
  • PD-Rx Pharmaceuticals Inc.
  • Perrigo Co.
  • Pharmaceutical Association
  • Pharmaceutical Utilization Management Program VA Inc.
  • Pharmacia Inc.
  • Pharmedix
  • Physicians Total Care Inc.
  • Poly Pharmaceuticals Inc.
  • Preferred Pharmaceuticals Inc.
  • Prepackage Specialists
  • Prepak Systems Inc.
  • Prescript Pharmaceuticals
  • Prescription Dispensing Service Inc.
  • Publix Super Markets
  • Qualitest
  • Rebel Distributors Corp.
  • Redpharm Drug
  • Remedy Repack
  • Resource Optimization and Innovation LLC
  • Rite Aid Corp.
  • Sandhills Packaging Inc.
  • Shanghai Ziyuan Pharmaceutical Co. Ltd.
  • Shasun Chemicals & Drugs Ltd.
  • Southwood Pharmaceuticals
  • St Mary's Medical Park Pharmacy
  • Stat Rx Usa
  • Sunmark
  • Talbert Medical Management Corp.
  • Teva Pharmaceutical Industries Ltd.
  • UDL Laboratories
  • Ultras Pharmaceuticals Inc.
  • Va Cmop Dallas
  • Vangard Labs Inc.
  • Veratex Corp.
  • Vintage Pharmaceuticals Inc.
  • Vistapharm Inc.
  • Walgreen Co.
  • Watson Pharmaceuticals
  • Wyeth Pharmaceuticals
  • Xactdose Inc.
Dosage forms
FormRouteStrength
Tablet, extended releaseOral600 mg
CapsuleOral
Capsule; kitOral
CapsuleOral400 mg
CapsuleOral200 mg
Tablet, coatedOral256 mg/1
TabletOral400 mg/400mg
TabletOral600 mg/600mg
TabletOral800 mg/800mg
TabletOral300 mg
TabletOral600 mg
TabletOral200 mg
InjectionIntravenous800 mg/8mL
SolutionIntravenous100 mg
SuspensionOral100 mg
Tablet, chewableOral50 mg
TabletOral50 mg
LiquidOral100 mg/5mL
SolutionOral100 mg/5mL
SuspensionOral200 mg/10mL
Kit; tabletOral
Kit
KitTopical
KitOral; Topical
Kit
SuspensionOral
Suspension / dropsOral50 mg/1.25mL
Tablet, film coatedOral200 mg/1
TabletOral
Capsule, liquid filledOral200 mg/1
SuspensionOral100 mg/5mL
Capsule, coatedOral200 mg/1
Capsule, liquid filledOral220 mg/1
TabletOral100 mg/1
TabletOral400 mg/1
TabletOral800 1/1
TabletOral800 mg/1
Tablet, coatedOral200 mg/1
Tablet, coatedOral400 mg/1
Tablet, coatedOral600 mg/1
Tablet, coatedOral800 mg/1
Tablet, film coatedOral200 1/1
Tablet, film coatedOral400 mg/301
Tablet, film coatedOral400 mg/1
Tablet, film coatedOral400 mg/400mg
Tablet, film coatedOral600 mg/1
Tablet, film coatedOral600 mg/600mg
Tablet, film coatedOral800 mg/1
Tablet, film coatedOral800 mg/800mg
CapsuleOral200 mg/1
Tablet, sugar coatedOral
SuspensionOral50 mg/1.25mL
Tablet, chewableOral100 mg/1
Capsule, liquid filledOral
Tablet, coatedOral
SuspensionOral40 mg
Tablet, chewableOral100 mg
Tablet, coatedOral100 mg/1
TabletOral100 mg
SolutionIntravenous10 mg/mL
Injection, solutionIntravenous5 mg/ml
LiquidOral50 mg/1.25mL
TabletOral600 mg/1
TabletOral200 mg/1
TabletOral400 mg
KitOral
TabletOral400 mg/537mg
Tablet, sugar coatedOral200 mg/1
Tablet, film coatedOral200 1/2001
Tablet, film coatedOral256 mg/1
CreamTopical
KitOral
Tablet, film coatedOral
Prices
Unit descriptionCostUnit
Neoprofen 20 mg/2 ml vial304.5USD ml
Caldolor 400 mg/4 ml vial2.21USD ml
Caldolor 800 mg/8 ml vial1.58USD ml
Nuprin arthritis patch1.11USD patch
Ibuprofen powder1.04USD g
Nuprin muscle & joint patch1.03USD patch
Profen II 45-800 mg 12 Hour tablet0.69USD tablet
Motrin 800 mg tablet0.59USD tablet
Advil allergy sinus caplet0.5USD caplet
Ibu-drops 40 mg/ml suspension drops0.42USD ml
Motrin 600 mg tablet0.4USD tablet
Ibuprofen 800 mg tablet0.36USD tablet
Ibuprofen 400 mg tablet0.35USD tablet
Infant's motrin 50 mg/1.25 ml0.34USD ml
Childs ibuprofen susp drp0.33USD ml
Ibuprofen 600 mg tablet0.33USD tablet
Wal-profen cold & sinus cplt0.3USD caplet
Infant ibuprofen susp drop0.29USD ml
Motrin 400 mg tablet0.29USD tablet
CVS Pharmacy infant ibuprofen susp drop0.25USD ml
Infants medi-profen susp0.23USD ml
Advil cold & sinus caplet0.22USD caplet
Advil pm caplet0.22USD caplet
Soba profen cold-sinus tablet0.22USD tablet
Midol caplet0.21USD caplet
Advil migraine 200 mg capsule0.2USD capsule
Ibuprofen cold-sinus caplet0.2USD caplet
Motrin 100 mg caplet0.2USD caplet
Motrin pm caplet0.2USD caplet
Advil 200 mg liqui-gel capsule0.19USD capsule
Soba profen ib caplet0.19USD caplet
Motrin 100 mg tablet chew0.18USD tablet
Pub infants profenib drops0.18USD ml
Sm ibuprofen ib 100 mg tablet0.18USD tablet
Eck ibuprofen jr caplet0.17USD caplet
Ibuprofen pm caplet0.17USD caplet
Advil 200 mg caplet0.15USD capsule
Advil 200 mg gel caplet0.15USD caplet
Advil 200 mg tablet0.15USD tablet
Ibuprofen 100 mg tablet chew0.15USD tablet
Motrin ib 200 mg caplet0.15USD caplet
Apo-Ibuprofen 600 mg Tablet0.14USD tablet
CVS Pharmacy ibuprofen jr str 100 mg tablet0.14USD tablet
Nu-Ibuprofen 600 mg Tablet0.14USD tablet
Motrin ib 200 mg tablet0.13USD tablet
Motrin ib 200 mg gelcap0.12USD capsule
Nuprin 200 mg caplet0.12USD caplet
Wal-profen 200 mg caplet0.12USD caplet
Wal-profen 200 mg tablet0.12USD tablet
Eql ibuprofen 200 mg tablet0.1USD tablet
Nuprin 200 mg tablet0.1USD tablet
Apo-Ibuprofen 400 mg Tablet0.08USD tablet
Ibuprofen ib 200 mg tablet0.08USD tablet
Novo-Profen 400 mg Tablet0.08USD tablet
Apo-Ibuprofen 300 mg Tablet0.07USD tablet
Medi-profen 200 mg tablet0.07USD tablet
Ibuprofen 100 mg/5ml Suspension0.06USD ml
Ibuprofen 200 mg caplet0.06USD caplet
Child ibuprofen susp0.05USD ml
Children's medi-profen susp0.05USD ml
Children's motrin cold suspension0.05USD ml
CVS Pharmacy ibuprofen 200 mg tablet0.05USD tablet
Ibuprofen cold suspension0.05USD ml
I-prin 200 mg tablet0.05USD tablet
Novo-Profen 600 mg Tablet0.05USD tablet
Children's motrin cold0.04USD ml
Pv ibuprofen 200 mg caplet0.04USD caplet
Soba children's profenib susp0.04USD ml
Ibuprofen 200 mg tablet0.03USD tablet
CVS Pharmacy ibuprofen 200 mg caplet0.02USD caplet
Pv ibuprofen 200 mg tablet0.02USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5215755No1993-06-012010-06-01Us
US6599531No1997-06-102017-06-10Us
US6348216No1997-06-102017-06-10Us
US6342530No2000-11-142020-11-14Us
US6344479No2001-03-202021-03-20Us
US8415337No2012-03-022032-03-02Us
US6211246No1999-06-102019-06-10Us
US8883849No2002-01-172022-01-17Us
US9155718No2002-01-172022-01-17Us
US8263647No2002-05-302022-05-30Us
US7863287No2007-02-282027-02-28Us
US6251426No1998-06-252018-06-25Us
US6727286No2001-11-272021-11-27Us
US8735452No2009-09-302029-09-30Us
US9138404No2009-09-302029-09-30Us
US9114068No2009-09-302029-09-30Us
US8871810No2009-09-302029-09-30Us
US9012508No2010-09-142030-09-14Us
US9295639No2009-09-302029-09-30Us
US8067451No2006-07-182026-07-18Us
US8501228No2006-07-182026-07-18Us
US8318202No2006-07-182026-07-18Us
US8449910No2006-07-182026-07-18Us
US8309127No2006-07-182026-07-18Us
US8067033No2006-07-182026-07-18Us
US9649284No2009-09-302029-09-30Us
US9072710No2012-03-162032-03-16Us
US9072661No2012-03-162032-03-16Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)75-77.5U.S. Patent 3,228,831 U.S. Patent 3,385,886
water solubility21 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP3.97AVDEEF,A (1997)
logS-3.99ADME Research, USCD
Caco2 permeability-4.28ADME Research, USCD
pKa4.91SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.0684 mg/mLALOGPS
logP3.5ALOGPS
logP3.84ChemAxon
logS-3.5ALOGPS
pKa (Strongest Acidic)4.85ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area37.3 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity60.73 m3·mol-1ChemAxon
Polarizability23.76 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9927
Blood Brain Barrier+0.9619
Caco-2 permeable+0.8866
P-glycoprotein substrateNon-substrate0.759
P-glycoprotein inhibitor INon-inhibitor0.9705
P-glycoprotein inhibitor IINon-inhibitor0.9323
Renal organic cation transporterNon-inhibitor0.9323
CYP450 2C9 substrateNon-substrate0.7594
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.6877
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9305
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9881
CYP450 3A4 inhibitorNon-inhibitor0.9655
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9691
Ames testNon AMES toxic0.9894
CarcinogenicityCarcinogens 0.5553
BiodegradationReady biodegradable0.5142
Rat acute toxicity2.3092 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9719
hERG inhibition (predictor II)Non-inhibitor0.9734
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (11.4 KB)
Spectra
SpectrumSpectrum TypeSplash Key
GC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (1 TMS)GC-MSsplash10-02t9-1910000000-23f448d7be7d5cc35682
GC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (1 TMS)GC-MSsplash10-02t9-1910000000-cbe52d63986b68a2cec0
GC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (1 TMS)GC-MSsplash10-00di-9300000000-cc259b7768023e4cdba8
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-03di-3910000000-618880f8fd7b8ec3d473
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-02t9-1910000000-23f448d7be7d5cc35682
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-02t9-1910000000-cbe52d63986b68a2cec0
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-00di-9300000000-cc259b7768023e4cdba8
Mass Spectrum (Electron Ionization)MSsplash10-03xr-3900000000-e20ef3c30496e17720ba
MS/MS Spectrum - Quattro_QQQ 10V, N/ALC-MS/MSsplash10-03di-0910000000-90bf6813134491c9fbfd
MS/MS Spectrum - Quattro_QQQ 25V, N/ALC-MS/MSsplash10-001i-9800000000-56f599abc462380b648c
MS/MS Spectrum - EI-B (HITACHI RMU-6E) , PositiveLC-MS/MSsplash10-03di-3910000000-618880f8fd7b8ec3d473
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-03di-1900000000-f1b7a986fee133d97eb1
MS/MS Spectrum - , positiveLC-MS/MSsplash10-03di-0920000000-aa36b3244e32560bb9d5
1H NMR Spectrum1D NMRNot Applicable
1H NMR Spectrum1D NMRNot Applicable
13C NMR Spectrum1D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylpropanoic acids. These are compounds with a structure containing a benzene ring conjugated to a propanoic acid.
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Phenylpropanoic acids
Sub Class
Not Available
Direct Parent
Phenylpropanoic acids
Alternative Parents
Monocyclic monoterpenoids / Aromatic monoterpenoids / Phenylpropanes / Monocarboxylic acids and derivatives / Carboxylic acids / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
2-phenylpropanoic-acid / P-cymene / Aromatic monoterpenoid / Monocyclic monoterpenoid / Monoterpenoid / Phenylpropane / Monocyclic benzene moiety / Benzenoid / Monocarboxylic acid or derivatives / Carboxylic acid
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
monocarboxylic acid (CHEBI:5855)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Chavez ML, DeKorte CJ: Valdecoxib: a review. Clin Ther. 2003 Mar;25(3):817-51. [PubMed:12852704]
  2. Ouellet M, Falgueyret JP, Percival MD: Detergents profoundly affect inhibitor potencies against both cyclo-oxygenase isoforms. Biochem J. 2004 Feb 1;377(Pt 3):675-84. [PubMed:14510637]
  3. Gallego-Sandin S, Novalbos J, Rosado A, Gisbert JP, Galvez-Mugica MA, Garcia AG, Pajares JM, Abad-Santos F: Effect of ibuprofen on cyclooxygenase and nitric oxide synthase of gastric mucosa: correlation with endoscopic lesions and adverse reactions. Dig Dis Sci. 2004 Sep;49(9):1538-44. [PubMed:15481334]
  4. Murphey LJ, Williams MK, Sanchez SC, Byrne LM, Csiki I, Oates JA, Johnson DH, Morrow JD: Quantification of the major urinary metabolite of PGE2 by a liquid chromatographic/mass spectrometric assay: determination of cyclooxygenase-specific PGE2 synthesis in healthy humans and those with lung cancer. Anal Biochem. 2004 Nov 15;334(2):266-75. [PubMed:15494133]
  5. Sanchez-Fidalgo S, Martin-Lacave I, Illanes M, Motilva V: Angiogenesis, cell proliferation and apoptosis in gastric ulcer healing. Effect of a selective cox-2 inhibitor. Eur J Pharmacol. 2004 Nov 28;505(1-3):187-94. [PubMed:15556152]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Yes
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name
PTGS1
Uniprot ID
P23219
Uniprot Name
Prostaglandin G/H synthase 1
Molecular Weight
68685.82 Da
References
  1. Chavez ML, DeKorte CJ: Valdecoxib: a review. Clin Ther. 2003 Mar;25(3):817-51. [PubMed:12852704]
  2. Patrignani P: Aspirin insensitive eicosanoid biosynthesis in cardiovascular disease. Thromb Res. 2003 Jun 15;110(5-6):281-6. [PubMed:14592549]
  3. Gupta K, Kaub CJ, Carey KN, Casillas EG, Selinsky BS, Loll PJ: Manipulation of kinetic profiles in 2-aryl propionic acid cyclooxygenase inhibitors. Bioorg Med Chem Lett. 2004 Feb 9;14(3):667-71. [PubMed:14741265]
  4. Martic M, Tatic I, Markovic S, Kujundzic N, Kostrun S: Synthesis, biological activity and molecular modeling studies of novel COX-1 inhibitors. Eur J Med Chem. 2004 Feb;39(2):141-51. [PubMed:14987823]
  5. Hillarp A: [Acetylsalicylic acid resistance--clinical diagnosis with unclear mechanism]. Lakartidningen. 2004 Nov 4;101(45):3504-6, 3508-9. [PubMed:15575422]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  7. Yu L, Shi D, Ma L, Zhou Q, Zeng S: Influence of CYP2C8 polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide and ibuprofen enantiomers in vitro. Biopharm Drug Dispos. 2013 Jul;34(5):278-87. doi: 10.1002/bdd.1842. Epub 2013 Jun 3. [PubMed:23536207]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Modulator
General Function
Ubiquitin protein ligase binding
Specific Function
Suppresses apoptosis in a variety of cell systems including factor-dependent lymphohematopoietic and neural cells. Regulates cell death by controlling the mitochondrial membrane permeability. Appea...
Gene Name
BCL2
Uniprot ID
P10415
Uniprot Name
Apoptosis regulator Bcl-2
Molecular Weight
26265.66 Da
References
  1. Palayoor ST, J-Aryankalayil M, Makinde AY, Cerna D, Falduto MT, Magnuson SR, Coleman CN: Gene expression profile of coronary artery cells treated with nonsteroidal anti-inflammatory drugs reveals off-target effects. J Cardiovasc Pharmacol. 2012 Jun;59(6):487-99. doi: 10.1097/FJC.0b013e31824ba6b5. [PubMed:22668799]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Modulator
General Function
Transmembrane signaling receptor activity
Specific Function
Thrombomodulin is a specific endothelial cell receptor that forms a 1:1 stoichiometric complex with thrombin. This complex is responsible for the conversion of protein C to the activated protein C ...
Gene Name
THBD
Uniprot ID
P07204
Uniprot Name
Thrombomodulin
Molecular Weight
60328.72 Da
References
  1. Palayoor ST, J-Aryankalayil M, Makinde AY, Cerna D, Falduto MT, Magnuson SR, Coleman CN: Gene expression profile of coronary artery cells treated with nonsteroidal anti-inflammatory drugs reveals off-target effects. J Cardiovasc Pharmacol. 2012 Jun;59(6):487-99. doi: 10.1097/FJC.0b013e31824ba6b5. [PubMed:22668799]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Negative modulator
General Function
Serine-type endopeptidase activity
Specific Function
Converts the abundant, but inactive, zymogen plasminogen to plasmin by hydrolyzing a single Arg-Val bond in plasminogen. By controlling plasmin-mediated proteolysis, it plays an important role in t...
Gene Name
PLAT
Uniprot ID
P00750
Uniprot Name
Tissue-type plasminogen activator
Molecular Weight
62916.495 Da
References
  1. Palayoor ST, J-Aryankalayil M, Makinde AY, Cerna D, Falduto MT, Magnuson SR, Coleman CN: Gene expression profile of coronary artery cells treated with nonsteroidal anti-inflammatory drugs reveals off-target effects. J Cardiovasc Pharmacol. 2012 Jun;59(6):487-99. doi: 10.1097/FJC.0b013e31824ba6b5. [PubMed:22668799]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Transporter activity
Specific Function
FABP are thought to play a role in the intracellular transport of long-chain fatty acids and their acyl-CoA esters. FABP2 is probably involved in triglyceride-rich lipoprotein synthesis. Binds satu...
Gene Name
FABP2
Uniprot ID
P12104
Uniprot Name
Fatty acid-binding protein, intestinal
Molecular Weight
15207.165 Da
References
  1. Velkov T, Chuang S, Wielens J, Sakellaris H, Charman WN, Porter CJ, Scanlon MJ: The interaction of lipophilic drugs with intestinal fatty acid-binding protein. J Biol Chem. 2005 May 6;280(18):17769-76. Epub 2005 Feb 18. [PubMed:15722357]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Activator
General Function
Zinc ion binding
Specific Function
Nuclear receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the nuclear receptor binds to DNA specific PPAR response elements (PPRE...
Gene Name
PPARG
Uniprot ID
P37231
Uniprot Name
Peroxisome proliferator-activated receptor gamma
Molecular Weight
57619.58 Da
References
  1. Dill J, Patel AR, Yang XL, Bachoo R, Powell CM, Li S: A molecular mechanism for ibuprofen-mediated RhoA inhibition in neurons. J Neurosci. 2010 Jan 20;30(3):963-72. doi: 10.1523/JNEUROSCI.5045-09.2010. [PubMed:20089905]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Pdz domain binding
Specific Function
Involved in the transport of chloride ions. May regulate bicarbonate secretion and salvage in epithelial cells by regulating the SLC4A7 transporter. Can inhibit the chloride channel activity of ANO...
Gene Name
CFTR
Uniprot ID
P13569
Uniprot Name
Cystic fibrosis transmembrane conductance regulator
Molecular Weight
168139.895 Da
References
  1. Devor DC, Schultz BD: Ibuprofen inhibits cystic fibrosis transmembrane conductance regulator-mediated Cl- secretion. J Clin Invest. 1998 Aug 15;102(4):679-87. [PubMed:9710435]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Proton-dependent oligopeptide secondary active transmembrane transporter activity
Specific Function
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.
Gene Name
SLC15A1
Uniprot ID
P46059
Uniprot Name
Solute carrier family 15 member 1
Molecular Weight
78805.265 Da
References
  1. Omkvist DH, Trangbaek DJ, Mildon J, Paine JS, Brodin B, Begtrup M, Nielsen CU: Affinity and translocation relationships via hPEPT1 of H-X aa-Ser-OH dipeptides: evaluation of H-Phe-Ser-OH as a pro-moiety for ibuprofen and benzoic acid prodrugs. Eur J Pharm Biopharm. 2011 Feb;77(2):327-31. doi: 10.1016/j.ejpb.2010.12.009. Epub 2010 Dec 13. [PubMed:21147219]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Activator
General Function
Zinc ion binding
Specific Function
Ligand-activated transcription factor. Key regulator of lipid metabolism. Activated by the endogenous ligand 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine (16:0/18:1-GPC). Activated by oleyleth...
Gene Name
PPARA
Uniprot ID
Q07869
Uniprot Name
Peroxisome proliferator-activated receptor alpha
Molecular Weight
52224.595 Da
References
  1. Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA: Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem. 1997 Feb 7;272(6):3406-10. [PubMed:9013583]

Enzymes

Details
1. Cytochrome P450 2C9
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Mo SL, Zhou ZW, Yang LP, Wei MQ, Zhou SF: New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126. [PubMed:20167001]
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  4. Carlile DJ, Hakooz N, Bayliss MK, Houston JB: Microsomal prediction of in vivo clearance of CYP2C9 substrates in humans. Br J Clin Pharmacol. 1999 Jun;47(6):625-35. [PubMed:10383540]
  5. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Yu L, Shi D, Ma L, Zhou Q, Zeng S: Influence of CYP2C8 polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide and ibuprofen enantiomers in vitro. Biopharm Drug Dispos. 2013 Jul;34(5):278-87. doi: 10.1002/bdd.1842. Epub 2013 Jun 3. [PubMed:23536207]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the...
Gene Name
UGT1A1
Uniprot ID
P22309
Uniprot Name
UDP-glucuronosyltransferase 1-1
Molecular Weight
59590.91 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Retinoic acid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. Isoform 2 lacks transferase activity but acts as a negative reg...
Gene Name
UGT1A3
Uniprot ID
P35503
Uniprot Name
UDP-glucuronosyltransferase 1-3
Molecular Weight
60337.835 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Retinoic acid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 2 lacks trans...
Gene Name
UGT1A9
Uniprot ID
O60656
Uniprot Name
UDP-glucuronosyltransferase 1-9
Molecular Weight
59940.495 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Glucuronosyltransferase activity
Specific Function
UDPGTs are of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isozyme is active on polyhydroxylated estrogens (such as...
Gene Name
UGT2B4
Uniprot ID
P06133
Uniprot Name
UDP-glucuronosyltransferase 2B4
Molecular Weight
60512.035 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Glucuronosyltransferase activity
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds.Its unique specificity for 3,4-catechol estrogens and estriol su...
Gene Name
UGT2B7
Uniprot ID
P16662
Uniprot Name
UDP-glucuronosyltransferase 2B7
Molecular Weight
60694.12 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name
PTGS1
Uniprot ID
P23219
Uniprot Name
Prostaglandin G/H synthase 1
Molecular Weight
68685.82 Da
References
  1. Palayoor ST, J-Aryankalayil M, Makinde AY, Cerna D, Falduto MT, Magnuson SR, Coleman CN: Gene expression profile of coronary artery cells treated with nonsteroidal anti-inflammatory drugs reveals off-target effects. J Cardiovasc Pharmacol. 2012 Jun;59(6):487-99. doi: 10.1097/FJC.0b013e31824ba6b5. [PubMed:22668799]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Palayoor ST, J-Aryankalayil M, Makinde AY, Cerna D, Falduto MT, Magnuson SR, Coleman CN: Gene expression profile of coronary artery cells treated with nonsteroidal anti-inflammatory drugs reveals off-target effects. J Cardiovasc Pharmacol. 2012 Jun;59(6):487-99. doi: 10.1097/FJC.0b013e31824ba6b5. [PubMed:22668799]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Yamasaki K, Rahman MH, Tsutsumi Y, Maruyama T, Ahmed S, Kragh-Hansen U, Otagiri M: Circular dichroism simulation shows a site-II-to-site-I displacement of human serum albumin-bound diclofenac by ibuprofen. AAPS PharmSciTech. 2000 May 14;1(2):E12. [PubMed:14727845]
  2. Galantini L, Leggio C, Konarev PV, Pavel NV: Human serum albumin binding ibuprofen: a 3D description of the unfolding pathway in urea. Biophys Chem. 2010 Apr;147(3):111-22. doi: 10.1016/j.bpc.2010.01.002. Epub 2010 Jan 18. [PubMed:20117876]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent transport of organic anions such as taurocholate, the prostaglandins PGD2, PGE1, PGE2, leukotriene C4, thromboxane B2 and iloprost.
Gene Name
SLCO2B1
Uniprot ID
O94956
Uniprot Name
Solute carrier organic anion transporter family member 2B1
Molecular Weight
76709.98 Da
References
  1. Satoh H, Yamashita F, Tsujimoto M, Murakami H, Koyabu N, Ohtani H, Sawada Y: Citrus juices inhibit the function of human organic anion-transporting polypeptide OATP-B. Drug Metab Dispos. 2005 Apr;33(4):518-23. Epub 2005 Jan 7. [PubMed:15640378]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Faassen F, Vogel G, Spanings H, Vromans H: Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22. [PubMed:12954186]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Atpase activity, coupled to transmembrane movement of substances
Specific Function
May be an organic anion pump relevant to cellular detoxification.
Gene Name
ABCC4
Uniprot ID
O15439
Uniprot Name
Multidrug resistance-associated protein 4
Molecular Weight
149525.33 Da
References
  1. Reid G, Wielinga P, Zelcer N, van der Heijden I, Kuil A, de Haas M, Wijnholds J, Borst P: The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9244-9. Epub 2003 Jun 30. [PubMed:12835412]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Transporter activity
Specific Function
Mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotre...
Gene Name
ABCC1
Uniprot ID
P33527
Uniprot Name
Multidrug resistance-associated protein 1
Molecular Weight
171589.5 Da
References
  1. Reid G, Wielinga P, Zelcer N, van der Heijden I, Kuil A, de Haas M, Wijnholds J, Borst P: The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9244-9. Epub 2003 Jun 30. [PubMed:12835412]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibit...
Gene Name
SLCO1A2
Uniprot ID
P46721
Uniprot Name
Solute carrier organic anion transporter family member 1A2
Molecular Weight
74144.105 Da
References
  1. Shitara Y, Sugiyama D, Kusuhara H, Kato Y, Abe T, Meier PJ, Itoh T, Sugiyama Y: Comparative inhibitory effects of different compounds on rat oatpl (slc21a1)- and Oatp2 (Slc21a5)-mediated transport. Pharm Res. 2002 Feb;19(2):147-53. [PubMed:11883641]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
Gene Name
SLC22A6
Uniprot ID
Q4U2R8
Uniprot Name
Solute carrier family 22 member 6
Molecular Weight
61815.78 Da
References
  1. Mulato AS, Ho ES, Cihlar T: Nonsteroidal anti-inflammatory drugs efficiently reduce the transport and cytotoxicity of adefovir mediated by the human renal organic anion transporter 1. J Pharmacol Exp Ther. 2000 Oct;295(1):10-5. [PubMed:10991954]
  2. Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther. 2002 Aug;302(2):666-71. [PubMed:12130730]
  3. Uwai Y, Saito H, Inui K: Interaction between methotrexate and nonsteroidal anti-inflammatory drugs in organic anion transporter. Eur J Pharmacol. 2000 Dec 1;409(1):31-6. [PubMed:11099697]
  4. Apiwattanakul N, Sekine T, Chairoungdua A, Kanai Y, Nakajima N, Sophasan S, Endou H: Transport properties of nonsteroidal anti-inflammatory drugs by organic anion transporter 1 expressed in Xenopus laevis oocytes. Mol Pharmacol. 1999 May;55(5):847-54. [PubMed:10220563]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenad...
Gene Name
SLC22A8
Uniprot ID
Q8TCC7
Uniprot Name
Solute carrier family 22 member 8
Molecular Weight
59855.585 Da
References
  1. Cha SH, Sekine T, Fukushima JI, Kanai Y, Kobayashi Y, Goya T, Endou H: Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol. 2001 May;59(5):1277-86. [PubMed:11306713]
  2. Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther. 2002 Aug;302(2):666-71. [PubMed:12130730]
  3. Kobayashi Y, Ohshiro N, Tsuchiya A, Kohyama N, Ohbayashi M, Yamamoto T: Renal transport of organic compounds mediated by mouse organic anion transporter 3 (mOat3): further substrate specificity of mOat3. Drug Metab Dispos. 2004 May;32(5):479-83. [PubMed:15100168]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates saturable uptake of estrone sulfate, dehydroepiandrosterone sulfate and related compounds.
Gene Name
SLC22A11
Uniprot ID
Q9NSA0
Uniprot Name
Solute carrier family 22 member 11
Molecular Weight
59970.945 Da
References
  1. Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther. 2002 Aug;302(2):666-71. [PubMed:12130730]
  2. Cha SH, Sekine T, Kusuhara H, Yu E, Kim JY, Kim DK, Sugiyama Y, Kanai Y, Endou H: Molecular cloning and characterization of multispecific organic anion transporter 4 expressed in the placenta. J Biol Chem. 2000 Feb 11;275(6):4507-12. [PubMed:10660625]

Drug created on June 13, 2005 07:24 / Updated on August 15, 2018 09:48